Staphylococcal Toxic Shock Syndrome

On this page

Quick Reference

RxDrug of choiceClindamycin 600 mg IV q8h (adults) or 15 mg/kg/dose IV q8h (children) plus a beta-lactam (cefazolin 2 g IV q8h or nafcillin 2 g IV q4h) for MSSA; vancomycin for MRSA.

AltAlternativesLinezolid 600 mg IV q12h (if clindamycin resistance); daptomycin 8-10 mg/kg IV q24h for MRSA.

⊘AvoidCorticosteroids (no benefit, may worsen outcomes); NSAIDs (associated with increased STSS risk).

DxTest of choiceClinical diagnosis based on fever, hypotension, rash, multi-organ dysfunction. Cultures (blood, wound, vaginal) and toxin gene testing (PCR for tst-1, seb, sec) supportive.

ScKey scoreCDC clinical case definition (fever ≥38.9°C, hypotension, diffuse erythroderma, desquamation, ≥3 organ systems), but not sensitive for early diagnosis.

→When to referAll patients to ICU; surgery for source control (debridement of necrotizing fasciitis); infectious disease consultation.

Staphylococcal TSS is a toxin-mediated emergency. Immediate source control and empiric antitoxin antibiotics (beta-lactam + clindamycin) are life-saving. IVIG is reserved for refractory shock. Do not wait for CDC criteria to initiate treatment.

Staphylococcal toxic shock syndrome (TSS) is a rare but life-threatening acute illness caused by superantigen-producing strains of [[Staphylococcus aureus]]. It is characterized by the abrupt onset of fever, hypotension, diffuse erythroderma, and multi-organ dysfunction due to a massive cytokine storm. Menstrual TSS, associated with tampon use, carries a mortality of approximately 8%, while nonmenstrual and streptococcal TSS (STSS) have mortality rates up to 38-63%. The cornerstone of management is immediate source control (removal of foreign bodies, drainage of abscesses) combined with empiric antitoxin antibiotics, a beta-lactam or vancomycin plus clindamycin, and intensive supportive care. Adjunctive intravenous immunoglobulin (IVIG) is reserved for refractory shock. Early recognition and treatment are critical, as the classic CDC surveillance criteria are met in only 52% of patients at admission.

Overview and Recommendations

Background

•Staphylococcal toxic shock syndrome (TSS) is a toxin-mediated illness caused by strains of that produce superantigens, primarily (TSST-1) in menstrual cases, and staphylococcal enterotoxins B and C in nonmenstrual cases. These superantigens bypass conventional antigen presentation, directly binding to MHC class II and T-cell receptor Vβ regions, activating up to 20% of the T-cell repertoire and triggering a cytokine storm that causes capillary leak, refractory hypotension, and multi-organ failure.
•Menstrual TSS (mTSS) accounts for roughly half of all staphylococcal TSS cases, with an incidence of 0.03-0.50 per 100,000 population annually. Classic risk factors include tampon use in young women aged 15-25 years, with TSST-1-producing strains of clonal complex 30 MSSA predominating. Nonmenstrual TSS, now more common than menstrual cases, occurs post-surgery, postpartum, or in association with focal S. aureus infections such as abscesses, sinusitis, or burns.
•Host susceptibility is critical: approximately 80-90% of healthy adults lack neutralizing antibodies to TSST-1, making them vulnerable to TSS when colonized or infected with a toxin-producing strain. The absence of such antibodies is a recognized risk factor, and a recombinant TSST-1 vaccine (rTSST-1v) is in development.
•Untreated TSS has a mortality approaching 100% in severe cases. With modern management, mTSS mortality is ~8% overall, but nonmenstrual and streptococcal TSS (STSS) carry mortality rates of 30-40% and up to 63% respectively. The paradigm shift in management, from simple beta-lactam therapy to routine inclusion of a protein synthesis inhibitor (clindamycin) to suppress toxin production, followed observational data showing reduced mortality with clindamycin, now supported by the SNAP trial protocol.
•Two distinct clinical entities exist: staphylococcal TSS (caused by S. aureus) and (STSS, caused by Streptococcus pyogenes). While clinically indistinguishable, STSS more often involves necrotizing fasciitis, bacteremia, and higher mortality. Empiric therapy must cover both organisms until cultures are definitive.

Evaluation

•Suspect staphylococcal TSS in any patient, especially a menstruating woman, postoperative patient, or burn victim, who presents with abrupt onset of fever ≥38.9°C, hypotension (systolic BP <90 mmHg), and diffuse erythroderma (sunburn-like rash) that may be subtle in dark skin.
•Ask about recent tampon use, menstrual cup use, nasal packing, surgical wounds, skin infections, or intrauterine devices. In children, inquire about recent skin infections, burns, and varicella exposure.
•Examine for conjunctival injection, pharyngeal erythema, strawberry tongue, and peripheral edema. Look for desquamation of palms and soles, which typically occurs 1-2 weeks after onset and is a late sign.
•Assess for multi-organ involvement: gastrointestinal (vomiting, diarrhea), muscular (severe myalgia, CK ≥300 U/L), renal (creatinine >2× upper limit), hepatic (bilirubin or transaminases >2× limit), hematologic (platelets <100,000/µL, WBC <4,000/µL), and central nervous system (altered consciousness without focal signs).
•Order blood cultures (two sets), note that cultures are positive in <5% of menstrual TSS but more often in nonmenstrual and streptococcal cases. Obtain cultures from any potential source: vaginal, wound, surgical site, or nasal.
•Perform laboratory studies: CBC with differential (leukopenia is a poor prognostic sign), serum creatinine, liver enzymes, CK, coagulation panel (PT, aPTT, fibrinogen, D-dimer), lactate, and procalcitonin. A CK ≥300 U/L and WBC <4,000/µL are biomarkers associated with STSS.
•Imaging: chest X-ray to evaluate for ARDS; abdominal/pelvic CT if source is unclear (may reveal abscess, ascites, or retained foreign body). Echocardiography if endocarditis is suspected.
•The CDC clinical case definition requires fever, hypotension, diffuse erythroderma, desquamation (1-2 weeks later), and involvement of ≥3 organ systems. However, this definition was designed for surveillance, not bedside diagnosis. At ICU admission, only 52% of confirmed mTSS cases meet even probable criteria, do not delay treatment pending fulfillment of all criteria.
•Key differential diagnoses: streptococcal TSS (often with necrotizing fasciitis), (no hypotension, coronary aneurysms), scarlet fever (pharyngitis, sandpaper rash, no hypotension), septic shock (positive blood cultures, no rash), drug reaction with eosinophilia (DRESS), meningococcemia (petechiae, meningitis), and toxic epidermal necrolysis (blistering, skin detachment).
•In children, the presentation may be atypical: rash is less prominent, pulmonary involvement (85%) and coagulopathy (92%) are common. Maintain a low threshold for empiric TSS treatment in a child with unexplained shock, fever, and any organ dysfunction.

Management

•Immediate source control is the highest priority: remove all foreign bodies (tampons, menstrual cups, nasal packing, surgical drains), drain abscesses, and debride any necrotic tissue. In necrotizing fasciitis, radical debridement must be performed within 12 hours of diagnosis.
•Start empiric intravenous antibiotics covering both S. aureus and Streptococcus pyogenes, including a toxin-suppressing agent. First-line: an anti-staphylococcal beta-lactam (cefazolin 2 g IV q8h or nafcillin 2 g IV q4h) plus clindamycin 600 mg IV q8h (adults) or 15 mg/kg/dose IV q8h (children, max 600 mg/dose). If MRSA risk is high (previous colonization, local prevalence >10%, recent healthcare exposure), replace the beta-lactam with vancomycin 15-20 mg/kg IV q8-12h targeting trough 15-20 mcg/mL.
•Clindamycin is the cornerstone anti-toxin agent; it suppresses exotoxin production at subinhibitory concentrations. The recommended duration of adjunctive clindamycin is 5 days, based on the SNAP trial protocol. If clindamycin resistance is suspected or documented (D-test positive), substitute linezolid 600 mg IV q12h.
•Admit all patients with TSS to the intensive care unit for hemodynamic monitoring and supportive care. Initiate balanced crystalloid fluid resuscitation (e.g., lactated Ringer's), but avoid excessive fluid given the capillary leak. Start norepinephrine as first-line vasopressor to maintain MAP ≥65 mmHg; add vasopressin or epinephrine if shock persists.
•Consider intravenous immunoglobulin (IVIG) for patients with refractory shock despite optimal source control and antibiotics. The typical dose is IVIG 0.5-1 g/kg as a single dose, repeated once after 24-48 hours if no response. Evidence is mixed, observational studies suggest benefit, but a recent propensity-matched analysis found no survival advantage after adjusting for immortal time bias. Reserve IVIG for the sickest patients.
•Provide lung-protective mechanical ventilation (tidal volume 6 mL/kg ideal body weight) for ARDS or airway protection. Monitor for acute kidney injury, coagulopathy, and hepatic dysfunction.
•Avoid corticosteroids: there is no evidence of benefit in TSS, and they may worsen outcomes. Avoid nonsteroidal anti-inflammatory drugs (NSAIDs), which are associated with increased risk of STSS.
•Once culture and susceptibility results are available (48-72 hours), de-escalate therapy. For MSSA, switch from vancomycin to cefazolin or nafcillin, this improves outcomes. For MRSA, continue vancomycin or daptomycin 8-10 mg/kg IV q24h. If GAS is confirmed, continue beta-lactam plus clindamycin (or linezolid).
•Monitor for complications: arrhythmias, septic cardiomyopathy, DVT/PE (start pharmacologic prophylaxis once bleeding risk is acceptable), pressure injuries, and hospital-acquired infections. Begin early mobilization after hemodynamic stability.
•The total duration of antibiotic therapy is 7-14 days, depending on source control adequacy. The 5-day course of clindamycin should be completed even if the beta-lactam is changed. IV-to-oral switch is appropriate when the patient is afebrile for 48 hours and hemodynamically stable; clindamycin has excellent oral bioavailability (450 mg PO q8h).
•Consult infectious disease and surgical services early. For any patient with necrotizing fasciitis, urgent surgical debridement is mandatory. Discharge criteria: hemodynamic stability without vasopressors, afebrile for 48 hours, tolerating oral antibiotics, no ongoing organ failure, and adequate source control.

Board Review — High Yield

•Superantigen, Bypasses conventional antigen processing, binds directly to MHC class II and TCR Vβ, activating up to 20% of T cells and causing a cytokine storm.
•TSST-1, Toxic shock syndrome toxin 1; the primary superantigen in menstrual TSS, encoded by the tst-1 gene on a mobile pathogenicity island.
•Clindamycin, Protein synthesis inhibitor that suppresses exotoxin production; cornerstone of anti-toxin therapy, given IV 600 mg q8h for 5 days.
•CDC criteria, Fever ≥38.9°C, hypotension, diffuse erythroderma, desquamation (1-2 weeks later), and involvement of ≥3 organ systems; designed for surveillance, not acute diagnosis.
•IVIG, Adjunctive therapy for refractory shock; dose 0.5-1 g/kg; evidence of benefit is confounded by immortal time bias.
•Source control, Immediate removal of foreign body and drainage of abscesses is the most critical intervention.
•D-test, Double disk diffusion test to detect inducible clindamycin resistance; positive result contraindicates clindamycin monotherapy.
•Mortality, Menstrual TSS ~8%; nonmenstrual and streptococcal TSS 30-63%.
•Kawasaki disease, Key differential: fever, rash, conjunctivitis, strawberry tongue, but no hypotension and coronary artery aneurysms on echo.
•SNAP trial, Protocol for adjunctive clindamycin 5 days, used as evidence for duration.

Deep Dive — Evidence Details

Definition, Classification and Causative Organisms

▸Staphylococcal TSS is caused by superantigen-producing S. aureus (TSST-1, enterotoxins); streptococcal TSS is caused by S. pyogenes and other beta-hemolytic streptococci.
▸Classification into menstrual vs nonmenstrual and staphylococcal vs streptococcal guides empiric therapy and source control.
▸Nonmenstrual TSS now exceeds menstrual TSS in incidence; STSS mortality remains high (38-63%).

HY High Yield: Menstrual TSS is strongly associated with TSST-1-producing CC30 MSSA; nonmenstrual TSS can involve enterotoxins B and C [41].

Toxic shock syndrome (TSS) is a condition caused by bacterial toxins. Symptoms may include fever, rash, skin peeling, and low blood pressure. There may also be symptoms related to the specific underlying infection such a — Toxic shock syndrome — Toxic shock syndrome (TSS) is a condition caused by bacterial toxins. Symptoms may include fever, rash, skin peeling, and low blood pressure. There ma...Wikipedia ↗

Staphylococcal toxic shock syndrome (TSS) is an acute, life-threatening, toxin-mediated illness characterized by fever, hypotension, diffuse rash, and multi-organ dysfunction, caused by superantigen-producing strains of Staphylococcus aureus . A clinically indistinguishable syndrome, (STSS), is caused by Streptococcus pyogenes ( , GAS) and, less commonly, by other beta-hemolytic streptococci ^[9]^D5^[12]^D5^[19]^B2b.

Also Called / Synonyms

Toxic shock syndrome (TSS)
Staphylococcal TSS
Menstrual TSS (mTSS)
Nonmenstrual TSS
Streptococcal toxic shock syndrome (STSS)
Toxic shock-like syndrome (historical term for STSS)

Classification

TSS is classified by causative organism and clinical setting. The distinction guides empiric therapy and source control.

Type	Causative Organism	Key Superantigen(s)	Typical Clinical Setting
Menstrual TSS	S. aureus (TSST-1-producing)	TSST-1	Tampon use in menstruating women ^[2]^C4^[11]^D5
Nonmenstrual TSS	S. aureus (TSST-1, enterotoxins B/C)	TSST-1, SEB, SEC	Focal infections (skin, soft tissue, post-surgical, burns) ^[41]^C4
Streptococcal TSS (STSS)	S. pyogenes (GAS)	SPE-A, SPE-C, SPE-F, SSA	, pneumonia, puerperal sepsis ^[12]^D5^[14]^B2c
Other streptococcal TSS	S. agalactiae (GBS), S. dysgalactiae subsp. equisimilis (SDSE), group G Streptococcus	Various superantigens	Invasive infections in immunocompromised hosts, elderly ^[19]^B2b^[21]^C4^[22]^C4

Causative Organisms

Staphylococcus aureus: The primary cause of menstrual and nonmenstrual TSS. Most menstrual cases are linked to TSST-1-producing strains of clonal complex (CC) 30 methicillin-sensitive S. aureus (MSSA) ^[41]^C4. Methicillin-resistant S. aureus (MRSA) clones, such as CC5 (New York/Japan epidemic clone), also carry the tst-1 gene and cause TSS, particularly in bloodstream infections ^[26]^B2b. Panton-Valentine leukocidin (PVL)-positive MSSA can produce a fulminant TSS-like syndrome with disseminated pustulosis and pancytopenia ^[48]^C4.
Streptococcus pyogenes (GAS): The dominant cause of STSS. emm types 1, 3, and 12 are overrepresented in invasive disease and STSS ^[14]^B2c^[46]^C4^[51]^C4. The M1UK lineage, associated with increased superantigen production, has driven recent outbreaks in Japan and elsewhere ^[40]^C4^[50]^C4.
Other beta-hemolytic streptococci: S. agalactiae (GBS), S. dysgalactiae subsp. equisimilis (SDSE), and group G Streptococcus can cause STSS, though less frequently than GAS ^[19]^B2b^[21]^C4^[22]^C4. GBS STSS is often associated with covR/S mutations that enhance virulence ^[42]^C4.

Clinical Significance

TSS is rare but carries high mortality: approximately 8% for menstrual TSS and up to 38-63% for STSS ^[2]^C4^[14]^B2c^[47]^C4. Incidence in the United Kingdom is 0.07 per 100,000 population, with nonmenstrual cases now more common than menstrual ^[41]^C4. In the United States, invasive GAS infections (including STSS) rose from 3.6 to 8.2 per 100,000 between 2013 and 2022 ^[23]^B2c. Prompt recognition and classification are essential because differs: staphylococcal TSS requires anti-toxin (e.g., clindamycin) and source control, while STSS additionally often needs surgical debridement and intravenous immunoglobulin ^[9]^D5^[17]^B2b.

Pearl: TSS is a clinical diagnosis; the absence of a recognized toxin-producing strain on culture does not exclude it, and empiric therapy should be initiated immediately based on the syndromic presentation.

Microbiology and Pathogenesis

▸Staphylococcal TSS is caused by superantigens (TSST-1, SEB, SEC) that bypass normal antigen processing and activate up to 20% of T cells, leading to a cytokine storm.
▸The tst-1 gene is carried on a mobile pathogenicity island; common lineages include CC30 MSSA and ST5-SCCmec II MRSA, the latter associated with high early mortality.
▸Toxin production is regulated by the Agr quorum-sensing system and modulated by environmental factors such as pH, oxygen, glucose, and tampon additives.

HY High Yield: Remember that TSST-1 is the classic menstrual TSS toxin, but nonmenstrual TSS can be caused by TSST-1, SEB, or SEC, all are superantigens that produce the same clinical picture.

! Warning: Absence of anti-TSST-1 antibodies is a major risk factor; patients without prior exposure may lack protective immunity. Tampon additives like GML reduce toxin production, but no product eliminates risk.

Staphylococcus aureus is a gram-positive spherically shaped bacterium, a member of the Bacillota, and is a usual member of the microbiota of the body, frequently found in the upper respiratory tract and on the skin. It i — Staphylococcus aureus — Staphylococcus aureus is a gram-positive spherically shaped bacterium, a member of the Bacillota, and is a usual member of the microbiota of the body,...Wikipedia ↗

The disease hinges on a single molecular event: a superantigen produced by specific Staphylococcus aureus strains bypasses conventional antigen presentation to unleash a systemic cytokine storm. The causative organism is Staphylococcus aureus , but only strains that carry the genetic capacity to produce one or more pyrogenic toxin superantigens cause toxic shock syndrome. The overwhelming majority of menstrual TSS cases are driven by (TSST-1), while nonmenstrual TSS may be caused by TSST-1, staphylococcal enterotoxin B (SEB), or staphylococcal enterotoxin C (SEC) ^[2]^C4^[9]^D5. Among these, TSST-1 accounts for nearly all menstrual cases and a substantial proportion of nonmenstrual cases ^[41]^C4.

Virulence Factors and Genomic Context

The tst-1 gene (encoding TSST-1) resides on a mobile (SaPI) that can be horizontally transferred between strains. The most common lineage in the UK is the 30 (CC30) methicillin-sensitive S. aureus (MSSA) lineage, which produces higher amounts of TSST-1 and has greater superantigen bioactivity than CC30 methicillin-resistant S. aureus (MRSA) strains ^[41]^C4. In Japan and other regions, an ST5-SCCmec II MRSA clone (the New York/Japan epidemic clone) carrying tst-1 is associated with particularly high early mortality in bloodstream infections ^[26]^B2b. A recently emerged ST22 lineage (ST22-PT) harbors both the Panton-Valentine leukocidin genes and tst-1, and has been linked to deep-seated skin infections and TSS-like symptoms ^[62]^C4.

Key superantigens in staphylococcal TSS:

Superantigen	Gene	Associated TSS type	Key clonal complexes
TSST-1	tst-1	Menstrual (classic), also nonmenstrual	CC30, CC5 (ST5-II), ST22-PT
Staphylococcal enterotoxin B (SEB)	seb	Nonmenstrual (often surgical site, pneumonia)	CC8, CC59
Staphylococcal enterotoxin C (SEC)	sec	Nonmenstrual	CC8

Superantigen Mechanism

Unlike conventional antigens, superantigens bind directly to the lateral surface of molecules on antigen-presenting cells and to the Vβ region of the without requiring antigen processing ^[9]^D5. This interaction activates up to 20% of the T-cell repertoire, compared with <0.1% for a conventional antigen. The result is a massive, simultaneous release of cytokines including TNF-α, IL-1, IL-6, and IFN-γ, a that causes capillary leak, refractory hypotension, and multi-organ dysfunction ^[9]^D5^[71]^D5.

In vitro studies using human vaginal epithelial cells (HVEC) have shown that TSST-1 reduces cell viability in a dose- and time-dependent manner, increases apoptosis, and induces a non-linear, dose-dependent transcriptional response involving chemokine signaling, cytokine-receptor interactions, and glycolysis pathways ^[71]^D5. These findings suggest that TSST-1 exerts direct cytotoxic and inflammatory effects on mucosal epithelium, contributing to the local portal of entry.

Regulation of Toxin Production

Expression of TSST-1 and other superantigens is tightly regulated by the (Agr) system, which is activated at high cell density via quorum sensing ^[36]^D5. Environmental factors further modulate toxin production:

pH: Neutral to slightly alkaline pH (6.5-7.5) enhances TSST-1 production.
Oxygen: Aerobic conditions favor toxin synthesis.
Glucose: Low glucose concentrations (as in the menstrual environment) upregulate TSST-1.
Tampon components: Certain tampon fibers and additives can alter toxin production. For example, glycerol monolaurate (GML) significantly reduces TSST-1 and alpha-toxin levels in vivo ^[1]^A1b. Other compounds such as chitosan malate inhibit both growth and exotoxin production ^[28]^D5, and various surfactants and isoprenoids suppress TSST-1 at subinhibitory concentrations ^[29]^D5.

Host Susceptibility

Approximately 10-20% of healthy individuals have detectable anti-TSST-1 antibodies; the absence of these antibodies is a recognized risk factor for developing TSS ^[2]^C4. The host immune response to S. aureus superantigens includes IgG production against multiple toxins, and higher antibody levels are associated with the presence of corresponding toxin genes in the infecting strain ^[55]^B3b. A vaccine candidate (rTSST-1v) has been shown to be safe and immunogenic, inducing neutralizing antibodies in healthy adults ^[53]^A1b.

Mechanism Flowchart

Pearl: The absence of neutralizing antibodies to TSST-1 is a key host susceptibility factor; any patient with unexplained shock, fever, and rash, especially a menstruating woman or a postoperative patient, should be evaluated for staphylococcal TSS, as the toxin-driven cytokine storm is rapidly reversible with source control and antitoxin .

Epidemiology, Transmission and Risk Factors

▸Staphylococcal TSS incidence is low (0.03-0.50 per 100 000) but stable; nonmenstrual TSS now exceeds menstrual TSS in many regions.
▸Household contacts of invasive GAS cases have a 2011‑fold higher risk of disease, warranting consideration of prophylaxis.
▸Injection drug use, homelessness, and long‑term care facility residence are the strongest contemporary risk factors for streptococcal TSS.

HY High Yield: Nonmenstrual TSS is now more common than menstrual TSS in the UK and US; children <16 years account for 39% of cases [41].

The superantigen-driven pathogenesis described above explains why the host's immune repertoire and the bacterial toxin load are central. The of staphylococcal TSS reflects this interplay: incidence is low but stable, with distinct risk profiles for menstrual and nonmenstrual cases.

Incidence and Demographics

Menstrual TSS (mTSS) incidence ranges from 0.03 to 0.50 per 100 000 people annually, with overall mortality around 8% ^[2]^C4. In the United Kingdom, the average annual incidence of all staphylococcal TSS is 0.07 per 100 000; nonmenstrual TSS now surpasses menstrual cases, and children <16 years account for 39% of all cases ^[41]^C4. In the United States, the incidence of Streptococcus pyogenes TSS (STSS) is higher, 3.8 / 100 000 for invasive GAS, with STSS comprising 11-14% of cases, and case-fatality rates for STSS reach 38% ^[14]^B2c^[77]^B3b. Staphylococcal TSS occurs in all age groups but peaks in adolescents and young adults (menstrual) and in the elderly (nonmenstrual) ^[41]^C4^[87]^C4.

Temporal Trends and Seasonal Variation

Staphylococcal TSS incidence has remained stable over recent decades ^[44]^B2c, but invasive GAS disease (including STSS) has surged globally since mid‑2022, coincident with relaxation of COVID‑19 restrictions ^[40]^C4^[85]^D5. In the United States, the incidence of invasive GAS rose from 3.6 to 8.2 per 100 000 between 2013 and 2022; the increase was greatest among adults aged 18-64 years ^[23]^B2c. A late‑summer to early‑autumn peak is observed for some GAS syndromes, though this pattern was attenuated in the 2023‑2024 post‑pandemic period ^[79]^A1a^[83]^B2b.

Risk Factors

Tampon use, the classic risk factor for mTSS, remains important, but the modern understanding includes the interplay of vaginal microbiome, TSST‑1-producing S. aureus carriage, and foreign‑body surface area ^[2]^C4^[11]^D5. Nonmenstrual TSS is driven by breaches of skin or mucosa: surgical wounds (including endoscopic sinus surgery, incidence 30 per 100 000 ^[80]^C4), thermal injury in children (mortality 8-18% ^[81]^C4), and postpartum or post‑abortion states ^[82]^C4. Intrauterine contraceptive devices confer a low but possible risk ^[82]^C4.

For streptococcal TSS, the dominant risk factors are age extremes, injection drug use, homelessness, residence in long‑term care facilities, chronic illness, and immunosuppression ^[14]^B2c^[23]^B2c^[78]^B2b. The risk of invasive GAS in household contacts of an index case is 2011‑fold higher than the population background rate ^[75]^B2b. Nosocomial transmission to healthcare workers has been documented ^[7]^C4.

Risk Factor	Odds Ratio / Relative Risk	Evidence Level
Injection drug use	~14‑fold higher incidence	2b ^[78]^B2b
Homelessness	17-80‑fold higher incidence	2b ^[78]^B2b
Age ≥65 years	9.4/100 000 incidence	2c ^[14]^B2c
Black race	4.7/100 000 incidence	2c ^[14]^B2c
emm type 1 or 3 (GAS)	Independent risk for death	2c ^[14]^B2c
Nonsteroidal anti‑inflammatory drugs	Independent risk for STSS	2b ^[46]^C4
Alcoholism	Independent risk for STSS	2b ^[46]^C4
Recent surgery	Independent risk for death	2c ^[14]^B2c
Chronic illness / immunosuppression	Independent risk for death	2c ^[14]^B2c
tst‑1 positive MRSA (BSI)	OR 2.61 (95% CI 1.19-6.03) for 2‑week mortality	2b ^[26]^B2b
Thermal injury (children)	Not quantified; mortality 8-18%	4 ^[81]^C4
Endoscopic sinus surgery	30 per 100 000 (0.03%)	4 ^[80]^C4

Transmission

S. aureus is transmitted via direct contact, fomites (e.g., tampons, nasal packing), and from colonized or infected individuals. Menstrual TSS is associated with vaginal colonization by TSST‑1-producing strains, amplified by tampon use ^[11]^D5. Nonmenstrual TSS follows infection of skin wounds, burns, surgical sites, or mucosal surfaces. The hypervirulent MRSA clone ST22‑PT, carrying both PVL and TSST‑1 genes, has emerged in Japan and several countries, highlighting the risk of international spread ^[62]^C4.

Pearl: The single strongest epidemiologic clue is nonmenstrual TSS in a patient with a recent skin infection, surgical wound, or burn, especially in children or elderly, and the risk of invasive GAS in household contacts is so high (RR 2011) that chemoprophylaxis should be considered.

Clinical Presentation

▸Clinical onset is rapid (hours to days) with fever, hypotension, and diffuse erythroderma as the classic triad.
▸Rash may be absent in up to 10% of cases, delaying diagnosis; desquamation occurs 1-2 weeks later.
▸Pulmonary involvement (85%) and coagulopathy (92%) are common in nonstreptococcal TSS.
▸CDC diagnostic criteria are insensitive at ICU admission (only 52% of confirmed mTSS meet criteria), so a high index of suspicion is needed.

HY High Yield: Always consider TSS in a young woman with fever, hypotension, and rash, even if she does not report tampon use, mTSS can occur with any menstrual product or even without menstruation [2].

! Warning: The absence of rash does not rule out TSS; up to 10% of patients never develop erythroderma, leading to fatal delays in antitoxin therapy [90].

The clinical syndrome unfolds rapidly, often within 24-48 hours of colonization or infection with a superantigen-producing strain. The incubation period is short, hours to a few days, and the presentation is dominated by the abrupt onset of fever, hypotension, and diffuse erythroderma, reflecting the systemic cytokine storm triggered by TSST-1 or staphylococcal enterotoxin B ^[2]^C4^[90]^C4.

Presenting Symptoms

Fever is universal, typically ≥38.9°C, and may be the first symptom ^[2]^C4.
Hypotension develops early, often requiring vasopressor support within hours of presentation; in a French multicenter ICU series, 84% of 102 patients with menstrual TSS required vasopressors ^[54]^B2b.
Diffuse erythroderma, a blanching, -like rash, appears in most patients and may be subtle in skin of color, where erythema is harder to detect; the rash later desquamates, especially on palms and soles, 1-2 weeks after onset ^[2]^C4^[60]^D5.
symptoms (nausea, vomiting, diarrhea) and myalgias are common early complaints ^[2]^C4.
Mucous membrane involvement includes conjunctival injection, pharyngeal erythema, and strawberry tongue; these features are discriminating but not present in every case ^[2]^C4.

Neurological Examination Findings

Neurological involvement typically reflects global hypoperfusion and cytokine-mediated encephalopathy rather than focal findings:

Altered mental status (confusion, agitation, somnolence) is frequent, sometimes progressing to coma ^[50]^C4.
Focal deficits are rare and should prompt evaluation for alternative diagnoses (e.g., meningitis, stroke).
In pediatric streptococcal TSS, meningismus may occur with concomitant meningitis, as reported in a fatal case of emm12 S. pyogenes meningitis in a 23-month-old ^[51]^C4.

Phenotypic Variants

Variant	Key Features	Frequency
Menstrual TSS (mTSS)	Associated with tampon use; TSST-1-producing S. aureus; peak age 15-25 years; presents with fever, rash, hypotension, and multisystem involvement	Most common form in young women ^[2]^C4^[54]^B2b
Nonmenstrual TSS	Post-surgical, postpartum, or associated with focal S. aureus infections (abscess, sinusitis, pneumonia); any age or sex; may lack rash ^[90]^C4	Up to 50% of staphylococcal TSS in some series ^[89]^C4
Streptococcal TSS (STSS)	Usually follows invasive GAS infection ( , pneumonia); more likely to have bacteremia; higher mortality (up to 39% in one series) ^[77]^B3b	11% of invasive GAS infections ^[77]^B3b
PVL-positive MSSA TSS	Presents with disseminated pustulosis and pancytopenia; mimics a toxin-driven process; responds to β-lactam de-escalation ^[48]^C4	Rare, emerging
Tattoo-associated TSS	Purpuric lesions at tattoo site; negative blood cultures; diagnosis confirmed by skin biopsy PCR for TSST-1 gene ^[66]^C4	Case reports

Red Flags

Rapidly progressive hypotension requiring vasopressors within hours ^[54]^B2b.
Clinical deterioration despite broad-spectrum , suggests toxin-mediated disease and need for antitoxin therapy (clindamycin, IVIG) ^[17]^B2b^[87]^C4.
Development of purpura fulminans (petechiae, hemorrhagic bullae, skin necrosis), indicates DIC and overlap with streptococcal TSS; carries high mortality ^[49]^C4.
Severe coagulopathy (elevated INR, thrombocytopenia, low fibrinogen), present in 92% of nonstreptococcal TSS in one pediatric series ^[87]^C4.
Pulmonary involvement (ARDS, bilateral infiltrates), seen in 85% of nonstreptococcal TSS ^[87]^C4.

Atypical Presentations

TSS without rash: Up to 10% of cases may lack erythroderma, leading to delayed diagnosis and treatment; maintained suspicion is essential, especially in postoperative patients ^[90]^C4.
Meningitis as the dominant feature: Rare but reported in children with emm12 S. pyogenes; STSS can present with fever, cough, and rapid progression to coma, mimicking bacterial meningitis ^[51]^C4.
Gastrointestinal prodrome: Nausea, vomiting, and diarrhea may precede shock by 12-24 hours, mimicking food poisoning or viral gastroenteritis; this is especially common in streptococcal TSS ^[49]^C4.
Altered mental status without focal signs: Encephalopathy may be the presenting complaint, particularly in older adults with diabetes ^[50]^C4.

Pearl: In a menstruating woman or postoperative patient with unexplained fever, hypotension, and diffuse erythroderma, initiate empiric antistaphylococcal therapy and source control immediately, do not wait for desquamation or blood culture results, as CDC criteria at admission are met in only 52% of confirmed mTSS ^[54]^B2b.

Diagnosis and Workup

▸The CDC case definition is the gold standard but is designed for surveillance, not bedside diagnosis; at ICU admission no patient with menstrual TSS met confirmed criteria, and only 52% met probable criteria [54].
▸Treatment should be initiated empirically based on the triad of fever, hypotension, and erythroderma plus multi-organ involvement, without waiting for desquamation or culture results [2,54].
▸A low WBC (<4,000/µL) and elevated CK (≥300 U/L) are additional biomarkers that support the diagnosis of streptococcal TSS [101].

Dx Diagnostic Essentials: Gold-standard test: The CDC clinical case definition (fever, hypotension, diffuse erythroderma, desquamation, multi-organ involvement). However, do not delay treatment if criteria are not fully met [2,54].

HY High Yield: In menstrual TSS, blood cultures are almost always sterile; vaginal cultures yield S. aureus in >90% of cases. Low WBC (<4,000/µL) and elevated CK (≥300 U/L) are bedside clues to STSS [54,101].

From the clinical presentation, the diagnosis hinges on recognizing the characteristic constellation of fever, hypotension, rash, and multi-organ dysfunction, but the classic CDC criteria have significant limitations when applied at the bedside ^[2]^C4^[54]^B2b.

History and Physical

The diagnosis of staphylococcal TSS is primarily clinical. Key elements to elicit:

Fever - typically abrupt onset, ≥38.9°C (102°F).
Hypotension - systolic blood pressure <90 mm Hg or orthostatic dizziness, often requiring vasopressor support in severe cases ^[54]^B2b.
Rash - diffuse erythroderma ( -like) that may be subtle; ask about recent tampon use, surgical wounds, or nasal packing ^[2]^C4^[90]^C4.
Desquamation - 1-2 weeks after onset, particularly on palms and soles; this is a late sign and not present at initial presentation ^[2]^C4.
Mucosal involvement - conjunctival injection, strawberry tongue, pharyngeal erythema.
Multi-organ involvement - at least three of: (vomiting, diarrhea), muscular (myalgia, creatine kinase elevation ≥300 U/L), renal (creatinine >2× upper limit), hepatic (bilirubin or transaminases >2× limit), hematologic (thrombocytopenia, WBC <4,000/µL), or central nervous system (altered consciousness) ^[2]^C4^[101]^B2b.

Ask about any foreign body (tampon, intrauterine device, nasal packing, surgical drain) and recent skin or soft tissue infection. In children, nonmenstrual cases often present with rash less prominent; pulmonary involvement (85%) and coagulopathy (92%) are common ^[87]^C4.

Gold-Standard Test

The CDC clinical case definition remains the gold standard for diagnosis, but it is important to recognize that this definition was designed for surveillance, not bedside diagnosis ^[2]^C4^[54]^B2b. The criteria require:

Fever ≥38.9°C
Hypotension (systolic <90 mm Hg)
Diffuse erythroderma
Desquamation (1-2 weeks later)
Involvement of ≥3 organ systems

Confirmed case: all five criteria met (including desquamation). Probable case: four of five criteria (no desquamation). However, in a large French ICU series of 102 patients with mTSS, no patient met confirmed criteria at admission, and only 52% met probable criteria ^[54]^B2b. The authors concluded that the CDC criteria should not be used for clinical diagnosis at ICU admission; instead, a lower threshold of fever, hypotension, erythroderma plus multi-organ dysfunction should trigger empiric treatment ^[54]^B2b.

Given the high mortality and rapid progression, treatment should not be delayed pending fulfillment of all CDC criteria ^[2]^C4^[54]^B2b.

Laboratory Studies

Test	Finding	Clinical Utility
Blood cultures	Positive in <5% of menstrual TSS; more often positive in nonmenstrual/streptococcal TSS ^[54]^B2b	Low yield; do not rule out TSS if negative
Vaginal/wound cultures	S. aureus isolated in >90% of menstrual TSS; toxin gene testing (TSST-1, enterotoxins)	Confirms superantigen-producing strain ^[2]^C4
White blood cell count	<4,000/µL is a biomarker for STSS (OR 7.8) ^[101]^B2b	Suggests toxin-mediated leukopenia
Creatine kinase	≥300 U/L is associated with STSS (OR 7.5) ^[101]^B2b	Reflects muscle involvement
C-reactive protein / procalcitonin	Markedly elevated (CRP often >150 mg/L); procalcitonin >0.5 ng/mL associated with PICU admission in children ^[99]^C4	Nonspecific but supports inflammation
Coagulation panel	Prolonged PT/PTT, thrombocytopenia, elevated D-dimer	Evidence of DIC
Renal/liver function	Elevated creatinine, transaminases, bilirubin	Organ involvement
Toxin gene detection	PCR for tst-1, sea, seb, sec on isolates	Identifies superantigen; not routinely available

In the French cohort, all blood cultures (n=102) were sterile, but vaginal cultures grew MSSA in 92/96, and 87% of those harbored TSST-1 ^[54]^B2b. In nonmenstrual TSS, cultures from wound or nasal sites are more likely to be positive.

Imaging

Imaging is not diagnostic but can identify sources or complications. Chest X-ray may show bilateral infiltrates or ARDS. Abdominal/pelvic CT can reveal , mesenteric edema, bowel wall thickening, or adnexal inflammation, and may identify a retained tampon or intrauterine device ^[59]^C4. Echocardiography is indicated if endocarditis is suspected. However, imaging may be normal in severe cases ^[59]^C4.

Diagnostic Algorithm

Step 1: At initial presentation with fever, hypotension, and rash, assess for involvement of ≥3 organ systems. If present, treat empirically for TSS without waiting for culture confirmation or desquamation ^[54]^B2b.

Step 2: Obtain appropriate cultures (blood, mucosal, wound, vaginal) and send for toxin gene testing if available. Collect samples for routine labs including CBC, CK, CRP, procalcitonin, coagulation, renal/hepatic function, and lactate.

Step 3: If cultures yield S. aureus and toxin gene is positive, the diagnosis is confirmed. If cultures are negative, the diagnosis remains probable based on clinical criteria. Treatment is identical.

Step 4: Initiate antitoxin (clindamycin 600 mg IV q8h in adults, 15 mg/kg/dose IV q8h in children) plus a beta-lactam (e.g., cefazolin 2 g IV q8h for MSSA, for MRSA) ^[3]^D5^[54]^B2b. Source control (removal of tampon, drainage of abscess) is urgent. IVIG (0.4 g/kg/day × 5 days) is considered for refractory shock ^[17]^B2b^[54]^B2b.

Step 5: Monitor for desquamation (1-2 weeks later) to confirm the CDC surveillance definition, but this does not alter .

Differential Diagnosis

TSS must be distinguished from other causes of shock with rash:

Streptococcal TSS - similar presentation but often with , higher mortality; GAS grows from blood or tissue ^[7]^C4^[97]^C4.
(KD) - fever, conjunctivitis, rash, strawberry tongue, but no hypotension; coronary artery aneurysms on echocardiography ^[93]^C4.
Scarlet fever - streptococcal pharyngitis with sandpaper rash, circumoral pallor, strawberry tongue; usually not hypotensive ^[43]^C4.
Drug reaction with eosinophilia and systemic symptoms (DRESS) - eosinophilia, lymphadenopathy, temporal association with drug; no hypotension.
Septic shock - positive blood cultures (gram-negative or other), no diffuse erythroderma; often focal source.
Meningococcemia - petechial/purpuric rash, meningitis, rapid progression; CSF findings confirm.
Toxic epidermal necrolysis (TEN) - widespread blistering with skin detachment, no shock.
Pediatric inflammatory multisystem syndrome (PIMS-TS) - temporally associated with SARS-CoV-2, myocardial dysfunction, less desquamation ^[93]^C4.

Pearl: When a menstruating woman or a patient with a foreign body presents with fever, hypotension, and any rash, treat empirically for TSS without waiting for fulfillment of CDC criteria, the evidence shows that strict application of surveillance criteria misses nearly half of cases at admission ^[54]^B2b.

Severity Assessment and Risk Stratification

▸No validated TSS-specific severity score exists; use general sepsis criteria (qSOFA, SOFA) and clinical shock to determine ICU need.
▸CDC criteria are insensitive for early diagnosis in critically ill patients; only 52% of ICU-admitted menstrual TSS patients met probable criteria at admission [54].
▸Risk factors for poor outcome include necrotizing fasciitis, young age, NSAID use, alcoholism, and emm/M3 types (for GAS) [46].

HY High Yield: CDC criteria are not sensitive for early TSS diagnosis in ICU patients; do not delay treatment while awaiting fulfillment of criteria [54].

Once the diagnosis of TSS is established or strongly suspected, the clinician must rapidly assess disease severity to determine the appropriate site of care (ward vs. ICU) and intensity of therapy. However, validated severity tools specific to TSS are lacking, and current practice relies on general sepsis criteria and recognition of high-risk features.

Clinical Severity Assessment

No TSS-specific severity score exists; clinicians should use general sepsis criteria ( , ) to identify organ dysfunction. The 2011 CDC criteria are not sensitive for early diagnosis in critically ill patients. In a French multicenter cohort of 102 patients with menstrual TSS admitted to the ICU, no patient met confirmed CDC criteria at admission, and only 52% fulfilled probable criteria ^[54]^B2b. Key indicators of severity include need for vasopressors (84% of patients in that cohort), respiratory failure requiring tracheal intubation (21%), acute kidney injury, hepatic dysfunction, and coagulopathy ^[54]^B2b. Despite high vasopressor requirement, **ICU mortality was ** in menstrual TSS, suggesting a better prognosis than non-menstrual TSS or TSS associated with ^[54]^B2b.

Risk Factors for Poor Outcome

For streptococcal TSS, independent risk factors for severe disease include young age, NSAID use, alcoholism, and infection with emm/M3 types ^[46]^C4. For staphylococcal TSS, the presence of necrotizing fasciitis (NF) portends a high mortality: 34% of patients with NF and shock died within 7 days ^[46]^C4. In periorbital NF, TSS was significantly associated with mortality (p<0.001) ^[103]^C4. Other risk factors include underlying immunocompromise (e.g., ^[105]^C4), diabetes ^[109]^C4, and intrauterine devices (fatal case reported ^[108]^C4).

Risk Factor	Population	Evidence
Young age, NSAID use, alcoholism, emm/M3 type	Streptococcal TSS	^[46]^C4
Necrotizing fasciitis with shock	Streptococcal/staphylococcal TSS	^[46]^C4
Periorbital NF with TSS	Staphylococcal TSS	^[103]^C4
Immunocompromise (e.g., Down syndrome)	Post-burn pediatric TSS	^[105]^C4
Diabetes	Invasive GBS with TSS	^[109]^C4
Intrauterine device	Menstrual TSS	^[108]^C4

Implications for Site of Care and Therapy Intensity

Any patient with TSS and evidence of shock or organ failure should be managed in an ICU. Early recognition of high-risk features (NF, vasopressor dependence, respiratory failure) should prompt aggressive source control and antitoxin (e.g., clindamycin) ^[37]^D5. Adjunctive IVIG is used infrequently (8% in menstrual TSS ^[54]^B2b; 4% in NF with shock ^[92]^B2b) and has no apparent impact on mortality in NF with shock (adjusted OR 1.00) ^[92]^B2b; its role in TSS remains uncertain and is not guided by severity scores.

Pearl: In menstrual TSS, CDC criteria are not sensitive at ICU admission; rely on clinical shock and organ failure to trigger ICU care and antitoxin therapy, as mortality is low with prompt ^[54]^B2b.

Empiric Management, Acute Care and Source Control

▸Source control (removal of foreign body, surgical debridement) is the highest priority and must be performed immediately.
▸Empiric antibiotics must include a beta-lactam (or vancomycin if MRSA risk) plus clindamycin 600 mg IV q8h for 5 days to suppress exotoxin production.
▸IVIG is not routinely indicated; consider only for refractory shock, weighing the mixed evidence and potential for immortal time bias.

! Warning: Clindamycin resistance in S. aureus and S. pyogenes is increasing. In invasive GAS infections in the US, clindamycin nonsusceptibility rose from 12.7% in 2013 to 33.1% in 2022 [23] (2c). If local resistance rates exceed 10-15%, consider linezolid 600 mg IV q12h as the anti-toxin agent instead.

Once the severity assessment and risk stratification have identified a patient with suspected staphylococcal toxic shock syndrome, proceeds along three simultaneous axes: source control, empiric antimicrobial therapy, and intensive supportive care. The toxin-driven cytokine storm demands interventions that both eliminate the pathogen and neutralize the superantigen. Delays of even hours worsen outcomes ^[87]^C4.

Step 1: Immediate Source Control

Source control is the highest priority, it removes the nidus of toxin production. The clinician must:

Remove all foreign bodies. In menstrual TSS, this means removing the tampon, menstrual cup, or contraceptive device. In surgical TSS, remove drains, packing, and tissue expanders ^[119]^C4.
Drain and debride. Abscesses, infected collections, and necrotic tissue require urgent drainage or surgical debridement. In or myositis, radical debridement is life-saving and must be performed within 12 hours of diagnosis ^[15]^B2b.
Take cultures. Obtain blood cultures (two sets), cultures from wound, vaginal, or surgical sites, and expel any retained material for microbiologic analysis. Vaginal cultures yield S. aureus in >90% of menstrual TSS cases ^[54]^B2b.

Source control failure, e.g., retained tampon or undrained abscess, is a common cause of clinical deterioration despite .

Step 2: Empiric Antimicrobial Therapy

Choose an intravenous regimen that covers both Staphylococcus aureus and and includes an agent that suppresses exotoxin production. The core strategy: a beta-lactam backbone plus a protein synthesis inhibitor.

First-line regimen:

Anti-staphylococcal beta-lactam (e.g., 2 g IV q4h, 2 g IV q8h, or 2 g IV q24h) OR, if MRSA risk is high (previous colonization, local prevalence >10%, recent healthcare exposure), 15-20 mg/kg IV q8-12h (target trough 15-20 mcg/mL).

Alternative to clindamycin: 600 mg IV q12h. Linezolid also suppresses exotoxin production and is an option when clindamycin resistance is suspected or documented ^[110]^D5. However, clinical data in TSS are limited to in vitro and animal models.

Duration of adjunctive therapy: 5 days, based on the SNAP trial protocol ^[3]^D5. This balances toxin suppression against the risk of infection.

Step 3: Adjunctive Therapies

Intravenous immunoglobulin (IVIG) remains controversial. The rationale: IVIG neutralizes superantigens and reduces cytokine release. Observational studies have reported conflicting results:

Study	Population	Mortality reduction	Adjusted HR/OR (95% CI)
Linnér et al. 2014 ^[17]^B2b	STSS, adults	Yes	OR 5.6 (1.2-26.0) for survival
Carapetis et al. 2014 ^[75]^B2b	iGAS, severe	Yes (with clindamycin)	OR 0.12 (0.01-1.29)
Wullt et al. 2026 ^[114]^B2b	STSS, adults	No (after adjusting for immortal time bias)	HR 1.69 (0.66-4.30)
Kadri et al. 2017 ^[92]^B2b	NF with shock	No	OR 1.00 (0.55-1.83)

Immortal time bias may explain some of the apparent benefit in earlier studies ^[58]^D5. Current expert consensus reserves IVIG for patients with refractory shock or rapidly progressive disease despite source control and antibiotics. When used, the typical dose is IVIG 0.5-1 g/kg as a single dose, repeated once after 24-48 hours if no response.

Step 4: Supportive Care and Monitoring

Intensive care unit (ICU) admission is mandatory for any patient with hypotension, altered mental status, or organ failure. In the French menstrual TSS cohort, 84% required vasopressors and 21% mechanical ventilation ^[54]^B2b.
Fluid resuscitation: Balanced crystalloids (e.g., lactated Ringer's) are preferred over 0.9% saline to avoid hyperchloremic acidosis, though no trial specifically addresses TSS.
Vasopressors: is first-line; add or if shock persists. The goal is MAP ≥65 mm Hg.
Mechanical ventilation for ARDS or airway protection. Lung-protective ventilation (tidal volume 6 mL/kg ideal body weight) is standard.
Monitoring: Serial lactate, procalcitonin, creatinine, bilirubin, platelets, and coagulation profile. Reassess source control daily.
Avoid : There is no evidence of benefit in TSS, and they may worsen outcomes by further suppressing host immunity.

Step 5: Transition to Definitive Therapy

Once the causative organism and its susceptibility profile are known (usually within 48-72 hours), therapy can be narrowed. The definitive antibiotic choice, dose adjustments, and de-escalation strategy are detailed in the next section. For now, the key is to maintain the anti-toxin agent (clindamycin or linezolid) for the full 5-day course, even if the beta-lactam is changed.

Figure 1: Empiric management algorithm for staphylococcal toxic shock syndrome. IVIG is reserved for refractory shock. All patients require ICU-level care.

Controversies and Guideline Disagreement

Question	Position A	Position B	Strength of disagreement	Implication for practice
Should IVIG be used routinely in STSS?	Pro: improves survival (Linnér 2014, Carapetis 2014) ^[17]^B2b^[75]^B2b	Con: no benefit after adjusting for immortal time bias (Wullt 2026, Kadri 2017) ^[92]^B2b^[114]^B2b	Strong (contradictory adjusted results)	IVIG is not standard; use only in refractory shock as adjunctive rescue therapy.
Which anti-toxin agent: clindamycin or linezolid?	Clindamycin: strong observational data, established guideline recommendation ^[17]^B2b	Linezolid: near-universal susceptibility, similar mechanism, but limited clinical data ^[110]^D5	Moderate (different evidence quality)	Clindamycin remains first-line; linezolid is a reasonable alternative when clindamycin resistance is known or suspected.

Pearl: Source control and early empiric antibiotics with a toxin-suppressing agent (clindamycin 600 mg IV q8h for 5 days) are the only interventions consistently associated with improved survival; IVIG should be reserved for refractory shock, as its benefit remains unproven after adjusting for immortal time bias ^[58]^D5^[114]^B2b.

Observational Studies of IVIG in Streptococcal Toxic Shock Syndrome

Study	Population	Mortality reduction	Adjusted HR/OR (95% CI)
Linnér et al. 2014 ^[17]^B2b (2b)	STSS, adults	Yes	OR 5.6 (1.2-26.0) for survival
Carapetis et al. 2014 ^[75]^B2b (2b)	iGAS, severe	Yes (with clindamycin)	OR 0.12 (0.01-1.29)
Wullt et al. 2026 ^[114]^B2b (2b)	STSS, adults	No (after adjusting for immortal time)	HR 1.69 (0.66-4.30)
Kadri et al. 2017 ^[92]^B2b (2b)	NF with shock	No	OR 1.00 (0.55-1.83)

Definitive Therapy: Dosing, PK/PD, Duration and De-escalation

▸Clindamycin 600 mg IV q8h (or 450 mg PO q8h) for 5 days is the standard adjunctive toxin-suppressing agent; linezolid is an alternative when clindamycin is resistant or unavailable.
▸De-escalate from vancomycin to a β-lactam (cefazolin/nafcillin) once MSSA is confirmed; this improves bactericidal activity and reduces toxicity.
▸IVIG remains controversial: meta-analysis shows mortality reduction in streptococcal TSS, but pediatric and large US cohort studies show no benefit; use only in refractory shock with shared decision-making.
▸Total antibiotic duration is 7-14 days depending on source control; the 5-day clindamycin course is adjunctive, not the entire regimen.

Rx Drug of Choice: **Clindamycin** 600 mg IV q8h (or 450 mg PO q8h) for 5 days is the adjunctive toxin-suppressing agent of choice for both staphylococcal and streptococcal TSS [3].

! Warning: **Clindamycin resistance** is increasing: 22% of invasive GAS isolates in the US were clindamycin-nonsusceptible in 2017 [76]. In such cases, linezolid 600 mg IV/PO q12h is a preferred alternative [110].

Once the causative organism and its susceptibility profile are known, therapy shifts from empiric coverage to pathogen-directed, toxin-targeted regimens. The dual goals remain unchanged: eradicate the pathogen and suppress superantigen production. The choice of agent, dose, route, and duration hinges on the organism identified ( Staphylococcus aureus vs. Streptococcus pyogenes), its resistance phenotype, and the adequacy of source control.

Step 1: Confirm organism and susceptibility

Culture results from blood, wound, or sterile sites typically return within 48-72 hours. Determine methicillin susceptibility for S. aureus (MSSA vs. MRSA) and clindamycin susceptibility for both S. aureus and S. pyogenes. All GAS isolates remain susceptible to β-lactams ^[76]^B2b; clindamycin nonsusceptibility among invasive GAS reached 22% in 2017 in US surveillance ^[76]^B2b and is linked to specific emm types (77, 58, 11, 83, 92) ^[76]^B2b. For S. aureus, MRSA requires a glycopeptide or alternative; MSSA can be treated with a β-lactam.

Step 2: Select the definitive regimen

Beta-lactam backbone, For confirmed GAS or MSSA, use a high-dose intravenous β-lactam: cefazolin 2 g IV q8h (or an antistaphylococcal penicillin such as nafcillin 2 g IV q4h). In the setting of TSS caused by PVL-positive MSSA, early transition from to a β-lactam upon MSSA confirmation is considered a key therapeutic strategy ^[48]^C4. For MRSA, vancomycin (target trough 15-20 mg/L) or (8-10 mg/kg IV q24h) is appropriate.

Toxin-suppressing agent, Add clindamycin 600 mg IV q8h (adults) or 15 mg/kg/dose IV q8h (max 600 mg/dose) in children ^[3]^D5. The SNAP trial protocol uses a 5-day course of adjunctive clindamycin ^[3]^D5; oral clindamycin is permitted at 450 mg PO q8h (max licensed dose) ^[3]^D5. Clindamycin inhibits exotoxin synthesis at subinhibitory concentrations, a property maintained even in some resistant strains via the CovS two-component system ^[95]^D5. However, clindamycin resistance is a growing concern: in a 2015-2018 NSTI cohort, clindamycin-resistant β-hemolytic streptococci were associated with higher risk of limb loss (RR 1.86) ^[15]^B2b. For patients with documented clindamycin resistance or intolerance, 600 mg IV/PO q12h is a reasonable alternative, as it similarly attenuates toxin production ^[110]^D5.

Intravenous immunoglobulin (IVIG), Adjunctive IVIG is administered for patients with refractory shock despite optimal and source control. A meta-analysis of clindamycin-treated patients with streptococcal TSS reported a mortality drop from 33.7% to 15.7% with IVIG ^[73]^A1a. However, a large pediatric cohort found no survival benefit (4.5% mortality in both IVIG and non-IVIG groups) ^[111]^B2b, and a propensity-matched analysis of with shock showed no impact on mortality (adjusted OR 1.00) ^[92]^B2b. The choice of IVIG preparation may influence neutralization of superantigens, with significant variation across batches ^[112]^D5. Given the mixed evidence, IVIG is reserved for the sickest patients, typically at a dose of 1-2 g/kg (single dose or divided over 2-5 days) based on expert consensus.

Step 3: Dosing, PK/PD, and monitoring

Drug	Indication	Dose	Renal adjustment	Hepatic adjustment	Key monitoring
Clindamycin	Toxin suppression (S. aureus, GAS)	600 mg IV q8h (adult); 15 mg/kg/dose IV q8h (child, max 600 mg/dose)	No adjustment	No adjustment	Diarrhea, C. difficile
Vancomycin	MRSA	15-20 mg/kg IV q8-12h (target trough 15-20 mg/L)	Adjust based on CrCl	No adjustment	Trough level, renal function
Daptomycin	MRSA (alternative)	8-10 mg/kg IV q24h	Adjust for CrCl <30	No adjustment	CPK, myopathy
Linezolid	Toxin suppression (alternative)	600 mg IV/PO q12h	No adjustment	No adjustment	Platelet count, lactate
Cefazolin	MSSA	2 g IV q8h	Adjust for CrCl <50	No adjustment	Rash, eosinophilia

For vancomycin, therapeutic drug monitoring is essential: target AUC/MIC ≥400 (trough-based dosing is acceptable if AUC is not available). Clindamycin does not require routine TDM, but its oral bioavailability is high (90%) and the oral dose (450 mg q8h) is used for IV-to-oral switch when the patient is clinically stable ^[3]^D5.

Step 4: Duration and IV-to-oral switch

The total duration of definitive therapy depends on the source of infection and the adequacy of source control. For TSS associated with a drainable focus (e.g., abscess, retained tampon, surgical site), antibiotics should continue for 7-14 days after source control. The adjunctive clindamycin is given for 5 days ^[3]^D5; extended courses beyond 5 days are not supported by trial data and may increase the risk of Clostridioides difficile infection ^[3]^D5.

IV-to-oral switch is feasible when the patient is hemodynamically stable, afebrile for 48 hours, and able to tolerate oral medications. Clindamycin oral bioavailability is excellent, making it an ideal agent for step-down. For MSSA, cefadroxil or oral cephalexin can be used; for MRSA, linezolid (600 mg PO q12h) is the preferred oral agent with high bioavailability. Do not use oral vancomycin for systemic infections.

Step 5: De-escalation

Once cultures confirm the pathogen and susceptibilities, narrow the empiric spectrum. Stop gram-negative coverage (e.g., aminoglycosides, antipseudomonal β-lactams) if not indicated. If S. aureus is MSSA, discontinue vancomycin and switch to cefazolin or an antistaphylococcal penicillin ^[48]^C4. If MRSA, continue vancomycin or daptomycin. De-escalation to a β-lactam from vancomycin in MSSA TSS improves outcomes due to enhanced bactericidal activity and lower toxicity ^[48]^C4.

Controversies and Guideline Disagreement

Question	Position A	Position B	Strength	Implication for practice
IVIG use in TSS	IDSA-based meta-analysis, mortality reduction from 33.7% to 15.7% with IVIG+clindamycin ^[73]^A1a	Pediatric cohort, no mortality benefit (4.5% both groups) ^[111]^B2b; NF shock cohort, no benefit (adjusted OR 1.00) ^[92]^B2b	Strong (conflicting findings across populations)	Reserve IVIG for refractory shock; acknowledge uncertainty in children
Clindamycin vs. linezolid as adjunct	Clindamycin, extensive observational data, standard of care ^[9]^D5^[75]^B2b	Linezolid, near-universal GAS susceptibility, similar in vitro toxin suppression, but limited clinical data ^[110]^D5	Moderate (increasing clindamycin resistance may shift preference)	Consider linezolid when clindamycin resistance is documented or suspected

Pearl: For confirmed MSSA TSS, de-escalating from vancomycin to a β-lactam (cefazolin or nafcillin) is a critical step that improves outcomes; adjunctive clindamycin should be given for exactly 5 days and can be transitioned to oral once the patient is stable ^[3]^D5^[48]^C4.

History and Evolution of Treatment

▸The 2003 European IVIG trial in STSS, though underpowered (n=21), remains the only randomized evidence for adjunctive immunoglobulin in TSS and showed a 3.6-fold higher mortality in placebo recipients [128].
▸CA-MRSA strains capable of producing superantigens (SEB, SEC) forced the abandonment of beta-lactam monotherapy and established the need for toxin-suppressive regimens including clindamycin [136].
▸A phase 1 trial of a recombinant TSST-1 variant vaccine (rTSST-1v) demonstrated safety and immunogenicity, paving the way for a potential preventive strategy [53].

HY High Yield: The 2003 IVIG trial is the only randomized evidence for adjunctive immunoglobulin in TSS, despite its early termination, it showed significant improvement in organ failure scores and a mortality trend favoring IVIG [128].

The current definitive therapy, source control, that suppress toxin production, and adjunctive IVIG, was built over four decades of clinical observation, failed trials, and a single landmark randomized study. Understanding this timeline clarifies why some interventions endured and others were abandoned.

The 1980s: Discovery and the Tampon Connection

Toxic shock syndrome (TSS) was first described in 1978, but its link to Staphylococcus aureus and tampon use crystallized in 1981 when Bergdoll et al. identified staphylococcal enterotoxin F (later renamed TSST-1) in 93.8% of TSS-associated isolates ^[134]^B3b. The recognition that superabsorbent tampons promoted toxin production led to their removal from the market and a dramatic decline in menstrual TSS incidence ^[11]^D5. Initial was empiric: remove the tampon, provide aggressive fluid resuscitation, and administer beta-lactam antibiotics. The role of toxin suppression was not yet appreciated.

The 1990s: Clindamycin Enters, IVIG Tested

Clindamycin, a protein synthesis inhibitor, emerged as a cornerstone based on observational data showing reduced mortality when added to beta-lactams, though no randomized trial in staphylococcal TSS confirms this. The pivotal trial for IVIG came in 2003: a European randomized, double-blind, placebo-controlled study of 21 patients with (STSS) ^[128]^A1b. The trial was terminated early due to slow recruitment. In the placebo group, mortality was 3.6-fold higher (not statistically significant), but the IVIG arm showed a significant decrease in sepsis-related organ failure scores at days 2 and 3 (and 0.04) and increased plasma neutralizing activity against superantigens. Despite the small sample, this trial provided the evidence base for IVIG as adjunctive therapy in TSS, now extrapolated to staphylococcal cases.

The 2000s: CA-MRSA and Nonmenstrual TSS

By 2003, Fey et al. demonstrated that community-acquired MRSA (CA-MRSA) strains produce staphylococcal enterotoxins B and C and are genotypically related to nonmenstrual TSS (nmTSS) isolates ^[136]^B3b. This shifted the antibiotic paradigm: beta-lactam monotherapy was abandoned for nmTSS in favor of agents that cover MRSA and suppress toxin, or combined with clindamycin. The same study showed that CA-MRSA strains were typically resistant only to beta-lactams, making susceptibility testing essential.

Prevention and the GML Story

Glycerol monolaurate (GML) was identified as a tampon fiber finish that reduces S. aureus exotoxin production in vivo. In a randomized double-blind trial, tampons containing GML lowered TSST-1 and alpha-toxin levels and reduced vaginal interleukin-8, a proinflammatory cytokine ^[1]^A1b. GML was added to tampons as a preventive measure, though its impact on TSS incidence is difficult to quantify.

2010s-2020s: Vaccine and Novel Therapeutics

A recombinant detoxified TSST-1 variant vaccine (rTSST-1v) entered phase 1 testing in 2014. In 46 healthy volunteers, the vaccine was safe, well-tolerated, and immunogenic, with adverse event rates similar to placebo (76% vs 83%) ^[53]^A1b. This represents an important step toward a prophylactic vaccine.

For treatment, novel approaches have emerged:

Aptamer antagonist: A PEGylated aptamer targeting staphylococcal enterotoxin B with nanomolar affinity (Kd = 64 nM) reduced mortality in a mouse model ^[30]^D5.
Extracorporeal therapy: In a case of refractory STSS, sequential pathogen hemoperfusion (Seraph 100) followed by cell-directed immunomodulation (selective cytopheretic device) enabled vasopressor discontinuation within 4 days and ECMO decannulation by day 6 ^[138]^C4.
IVIG in pediatric TSS: A feasibility trial (n = 28) showed that a randomized trial of IVIG versus albumin 4% in pediatric TSS is feasible, though no difference in clinical outcomes was observed ^[120]^A1b.

What Was Abandoned and Why

Abandoned Practice	Reason	Evidence
Beta-lactam monotherapy for CA-MRSA TSS	Emergence of MRSA strains producing superantigens ^[136]^B3b	^[136]^B3b
for carriage eradication	Poor efficacy (38% eradication) ^[129]^A1b	^[129]^A1b
High-dose corticosteroids	No benefit in superantigen-mediated shock (no cited trial)	,

Pearl: The evolution of TSS treatment mirrors the shift from toxin neutralization to toxin suppression, clindamycin and IVIG target the superantigen cascade, not just bacterial clearance, and novel approaches (aptamers, extracorporeal therapy) aim to interrupt the cytokine storm at multiple points.

Antimicrobial Resistance and Stewardship

▸Clindamycin resistance in invasive GAS in the US rose from 12.7% (2013) to 33.1% (2022); all GAS remain susceptible to β-lactams.
▸In staphylococcal TSS, CA-MRSA with high clindamycin resistance (up to 63%) is common; vancomycin, daptomycin, and ceftobiprole retain activity.
▸Stewardship mandates a β-lactam backbone, D-test-guided clindamycin use, and linezolid as an alternative when clindamycin resistance is high.

! Warning: Clindamycin may upregulate exotoxins in resistant GAS strains via CovS activation - do not rely on clindamycin as sole anti-toxin therapy if resistance is suspected [95].

HY High Yield: Perform a D-test (double-disk diffusion) on all GAS and S. aureus isolates from TSS cases to detect inducible clindamycin resistance - a negative D-test supports clindamycin use, but high local resistance may still warrant linezolid.

Following the history of evolving treatment approaches, antimicrobial resistance now critically shapes therapeutic decisions for TSS. The superantigen-driven pathophysiology demands agents that suppress toxin production, yet rising resistance threatens the efficacy of traditional adjunctive therapies.

Resistance in (GAS)

GAS remains universally susceptible to β-lactams ^[76]^B2b^[142]^D5, but macrolide and lincosamide resistance has increased sharply. US surveillance data from 2006-2017 documented clindamycin nonsusceptibility (CliNS) rising to 22.0% by 2017; nearly all CliNS isolates were also erythromycin-resistant ^[76]^B2b. By 2022, combined macrolide-clindamycin nonsusceptibility reached 33.1% ^[23]^B2c.

Highest-risk emm types: emm types 77, 58, 11, 83, and 92 had >30% CliNS ^[76]^B2b.
Risk groups: young adults (18-34 years), persons experiencing homelessness, those who inject drugs, and long-term care facility residents are disproportionately affected ^[76]^B2b.
Clinical impact: In β-hemolytic streptococcal necrotizing infections, clindamycin resistance was associated with higher risk of limb loss (RR 1.86, not adjusted for confounders) ^[15]^B2b. In a fatal pediatric TSS case, an emm12 strain carried ermB and tetM, conferring resistance to macrolides, clindamycin, and tetracycline ^[51]^C4.

Resistance in Staphylococcus aureus

Community-associated MRSA (CA-MRSA) accounts for a substantial proportion of staphylococcal TSS isolates. A Taiwanese pediatric series found 69% oxacillin resistance and 63% clindamycin resistance among TSS isolates, all carrying ermB and mecA; isolates remained susceptible to , gentamicin, , and ^[16]^B3b. The New York/Japan epidemic clone (CC5, SCCmec II, TSST-1-positive) is multiresistant and linked to increased 2-week mortality in bloodstream infections (aOR 2.61 for MRSA) ^[26]^B2b. Newer agents (ceftobiprole, , tigecycline) show excellent in vitro activity against MRSA clones, including TSST-1 producers ^[31]^D5.

Stewardship Principles

Use a β-lactam backbone - penicillin or cefazolin (for GAS) or an antistaphylococcal β-lactam (for S. aureus) - to which near-universal susceptibility remains ^[76]^B2b^[142]^D5.
Select adjunctive toxin-suppressive therapy based on local antibiograms. When clindamycin resistance exceeds 15-20% or inducible resistance is detected (D-test positive), substitute (to which GAS and MRSA remain >99% susceptible) ^[110]^D5.
Avoid clindamycin monotherapy. In clindamycin-resistant GAS, clindamycin may paradoxically upregulate exotoxins (streptolysin O, NADase) via CovS activation ^[95]^D5.
Check for inducible resistance using the D-test before relying on clindamycin as a sole anti-toxin agent.
Consider combination therapy for TSS due to S. pyogenes as one of the few strong indications for antibiotic combinations ^[37]^D5.
Monitor local resistance trends. Ongoing genomic surveillance (emm typing, whole-genome sequencing) guides empiric choices ^[23]^B2c^[76]^B2b.

Pearl: When managing TSS of suspected streptococcal etiology, obtain a D-test on the isolate; if clindamycin resistance is present or local rates exceed 20%, replace clindamycin with linezolid while continuing a β-lactam - this approach preserves antitoxin activity without risking treatment failure.

Antimicrobial Resistance Patterns in TSS Pathogens

Pathogen	Drug	Resistance trend	Key observations
GAS	Clindamycin	14.6% (2011-2017) → 33.1% (2022)	Nearly all CliNS are EryNS; highest in emm11, 58, 77, 83, 92 ^[76]^B2b^[23]^B2c
GAS	Macrolides (erythromycin)	14.5% (2006-2017) → same as clindamycin trend	Parallel increase; linked to ermB carriage ^[76]^B2b^[51]^C4
GAS	β-lactams	0%	Universal susceptibility remains ^[76]^B2b^[142]^D5
S. aureus (CA-MRSA)	Clindamycin	63% resistant in Taiwanese pediatric TSS	High ermB carriage; CA-MRSA also oxacillin-resistant (69%) ^[16]^B3b
S. aureus (MRSA)	Vancomycin	0%	Susceptible; remains drug of choice ^[16]^B3b^[68]^D5
S. aureus (MRSA)	Daptomycin, ceftobiprole, tigecycline	>99% susceptible	MIC90 0.5, 2, 0.25 mg/L respectively ^[31]^D5
S. aureus (MSSA)	Clindamycin	Susceptible	tst+ CC30 MSSA lineage predominant in UK TSS ^[41]^C4

Complications

▸Respiratory failure is common; serial FVC and early intubation criteria should be applied.
▸Autonomic instability (arrhythmias, BP lability, ileus, urinary retention) requires proactive monitoring.
▸Long-term complications include renal, cardiovascular, and hepatic disease, especially in men.

HY High Yield: Long‑term morbidity after TSS is substantial: men have a 15‑year rehospitalization rate of 52% vs 30% in controls, with markedly elevated risks of renal (HR 17.43), cardiovascular (HR 2.57), and hepatic (HR 19.83) complications [84]. These patients require sustained follow‑up.

Even after source control and appropriate antimicrobial therapy, the clinical course of toxic shock syndrome (TSS) is frequently complicated by multi-organ dysfunction and nosocomial complications that require vigilant ICU-level supportive care. The superantigen-driven cytokine storm causes widespread tissue damage, and survivors face substantial long‑term morbidity.

Respiratory Monitoring

Acute respiratory failure, often from acute respiratory distress syndrome (ARDS) or shock-related pulmonary edema, is common. Serial bedside forced vital capacity (FVC) measurements help detect neuromuscular weakness, although no TSS-specific threshold exists. Standard ICU intubation criteria apply (see table).

Table 1. Intubation Criteria

Parameter	Threshold
Respiratory rate	>30 breaths/min
PaO₂/FiO₂	<200 mmHg
Hypercapnia	PaCO₂ >50 mmHg with pH <7.25
Altered mental status	≤8 or inability to protect airway
Hemodynamic instability	Refractory shock despite vasopressors

These thresholds are general ICU endpoints; prompt airway support prevents hypoxic injury and facilitates source control.

Autonomic Complications

Toxin-mediated inflammation can disrupt autonomic regulation. Arrhythmias (e.g., , ventricular tachycardia), labile blood pressure, ileus, and urinary retention are common. Echocardiography may reveal septic cardiomyopathy, a dynamic, reversible myocardial depression driven by cytokines and mitochondrial dysfunction ^[145]^D5. Serial hemodynamic phenotyping using echocardiography can guide fluid and vasopressor to avoid over‑resuscitation ^[145]^D5.

DVT/PE Prophylaxis

Critically ill TSS patients are at high risk for venous thromboembolism. Standard pharmacologic prophylaxis with or should be initiated once bleeding risk is deemed acceptable, following institutional protocols. Mechanical prophylaxis (intermittent pneumatic compression) may be added if pharmacologic agents are contraindicated.

Pain Management

Pain arises from incisions, drain sites, debrided wounds, and the general stress of critical illness. Multimodal is recommended: (650-1000 mg every 6 hours, not to exceed 4 g/day) combined with such as (2-4 mg IV as needed) or (25-50 mcg IV), with careful monitoring for hypotension and respiratory depression. Nonsteroidal anti‑inflammatory drugs are generally avoided due to renal and risks in this population.

Rehabilitation

Early mobilization should begin as soon as hemodynamic stability is achieved (typically after vasopressor weaning). Physiotherapy focuses on regaining strength, preventing contractures, and addressing critical illness myopathy. Occupational therapy aids in activities of daily living. Speech and swallowing assessment is indicated after prolonged intubation.

Hospital-Acquired Complications

Prevention bundles are essential:

: Elevate of bed 30-45°, daily sedation interruption, oral care with chlorhexidine.
Pressure injuries: Frequent turning, use of specialty mattresses.
Catheter-associated urinary tract infection: Remove urinary catheter as soon as possible.
Central line‑associated bloodstream infection: Strict sterile insertion and maintenance bundles.

Complication Table

Complication	Frequency	Prevention	Management
Acute kidney injury	Common (HR 17.43 for men ^[84]^B2b)	Maintain adequate perfusion, avoid nephrotoxins	Renal replacement therapy if indicated
Cardiac dysfunction	Common (HR 2.57 for CV hospitalization ^[84]^B2b)	Serial echocardiography, limit fluid overload	Inotropes, vasopressors as guided by hemodynamic phenotype ^[145]^D5
Hepatic injury	Elevated transaminases; HR 19.83 for hepatic hospitalization ^[84]^B2b	Avoid hepatotoxic drugs	Supportive care
Arrhythmia	Frequent in septic shock	Monitor telemetry, correct electrolytes	Antiarrhythmics, cardioversion if unstable
Ileus / urinary retention	Common due to autonomic dysfunction	Nasogastric tube, bladder scan	Prokinetics, intermittent catheterization
Mortality	8% (mTSS) ^[2]^C4; ~50% (STSS) ^[5]^C4; 8.3% (pediatric thermal injury) ^[81]^C4	Early recognition, source control, , IVIG	ICU support, toxin suppression
Long‑term rehospitalization	52.0 vs 30.0 per 100 for men at 15 years ^[84]^B2b	Continue follow‑up, monitor renal/CV/hepatic function	Multidisciplinary outpatient care

Pearl: The complications of TSS extend far beyond the acute episode; survivors face a substantially elevated risk of renal, cardiovascular, and hepatic morbidity for up to 15 years, justifying long‑term follow‑up ^[84]^B2b.

Prognosis and Natural History

▸Menstrual staphylococcal TSS carries a mortality rate near 0% with modern ICU care, whereas streptococcal TSS still kills 30-40% of patients.
▸Clindamycin is the only modifiable factor consistently associated with reduced mortality (OR 0.14); IVIG benefit is uncertain due to immortal time bias.
▸Age ≥65 years, necrotizing fasciitis, leukopenia, and tst-1 gene carriage in MRSA are independent predictors of death.

HY High Yield: The risk of death in STSS is highest in the first 48 hours; early recognition and source control are paramount.

Complications of TSS carry a high mortality risk; the natural history of untreated TSS is rapid progression to shock and death within hours to days. This section summarizes the untreated course, treated outcomes, and predictors of mortality, drawing on the best available evidence.

Untreated Course

Before the recognition of TSS and the institution of source control, , and intensive care, the case-fatality rate was extremely high. For streptococcal TSS (STSS), the mortality rate in the pre-antitoxin era was essentially 100% once shock developed. With modern , outcomes have improved but remain substantial.

Treated Outcomes

Treated outcomes vary by pathogen and patient population:

Menstrual staphylococcal TSS (mTSS): In a large French ICU series of 102 patients (median age 18 years), no patient died and none required amputation ^[54]^B2b. This reflects the young age, absence of bacteremia, and rapid recognition.
Nonmenstrual staphylococcal TSS: Mortality is higher, especially in the elderly and those with comorbidities. In a prospective study of S. aureus bloodstream infections, the all-cause 4-week mortality was 15.0% (85/567), with 76.5% of deaths occurring within the first 2 weeks ^[26]^B2b. Carriage of the tst-1 gene (TSST-1) was an independent risk factor for 2-week mortality (adjusted OR 2.61 in MRSA BSIs) ^[26]^B2b.
Streptococcal TSS: In US population-based surveillance (2000-2004), the case-fatality rate for STSS was 36% ^[148]^B2b. In a UK study, the 7-day mortality for severe GAS infections was approximately 20%, and for STSS it was 63% in New Zealand ^[46]^C4. A systematic review of 1918 patients with STSS reported a pooled mortality of approximately 30-40% despite modern therapy ^[149]^B2a.

Predictors of Mortality

Multiple factors independently predict death in TSS. The following table summarizes key predictors from the literature:

Predictor	Population	Effect (95% CI)	Source
Age ≥65 years vs 18-64 years	STSS	OR 2.37 (1.47-3.84)	^[149]^B2a
STSS diagnosis (vs other invasive GAS)	Invasive GAS	Case-fatality 36% vs 13.7% overall	^[148]^B2b
	STSS	Case-fatality 24-34%	^[148]^B2b, ^[46]^C4
Airway bleeding	PVL-positive S. aureus pneumonia	P=0.002	^[57]^B2b
Erythroderma within 24 h	PVL-positive S. aureus pneumonia	Independent predictor	^[57]^B2b
tst-1 carriage in MRSA BSI	S. aureus BSI	aOR 2.61 (1.19-6.03)	^[26]^B2b
Clindamycin treatment (protective)	STSS	OR 0.14 (0.06-0.37)	^[149]^B2a
IVIG treatment (protective, but uncertain)	STSS in clindamycin-treated patients	OR 0.34 (0.15-0.75) but low certainty; immortal time bias may explain	^[149]^B2a, ^[58]^D5, ^[114]^B2b

Note: The evidence for IVIG is confounded by immortal time bias. A Swedish population-based study adjusting for this bias found a hazard ratio of 1.69 for 30-day mortality ^[114]^B2b. The only randomized trial (in children) found no difference between IVIG and albumin ^[120]^A1b.

Special Populations

Pediatric burn-associated TSS: In a systematic review of 72 cases, the overall survival was 73.6% (53/72), with 8.3% mortality and 18% unreported outcome ^[81]^C4.
Postpartum S. aureus TSS: Rare, but may present with ; early recognition and treatment lead to recovery ^[104]^C4.
Menstrual TSS: Excellent prognosis with modern care; 0% mortality in the largest ICU series ^[54]^B2b.

Pearl: The single most modifiable predictor of survival in STSS is early administration of clindamycin (OR 0.14 for mortality); the benefit of IVIG remains unproven in randomized data and may be an artifact of immortal time bias ^[149]^B2a, ^[58]^D5.

Mortality Rates by TSS Type and Population

TSS Type / Population	Mortality Rate	Source
Menstrual staphylococcal TSS (ICU series)	0%	^[54]^B2b
S. aureus BSI (all-cause 4-week)	15.0%	^[26]^B2b
Streptococcal TSS (US surveillance)	36%	^[148]^B2b
Streptococcal TSS (New Zealand)	63%	^[47]^C4
Pediatric burn-associated TSS	8.3% (73.6% survival)	^[81]^C4
PVL-positive S. aureus necrotizing pneumonia	56%	^[57]^B2b

Prevention and Infection Control

▸No licensed vaccine exists; rTSST-1v vaccine is in phase 1 development showing safety and persistent neutralizing antibodies [53][158].
▸Household contacts of invasive GAS have a 2000-fold increased risk of TSS; antibiotic prophylaxis should be considered [75].
▸Prophylactic systemic antibiotics with nasal packing or in burn patients do not prevent TSS in most settings [153][154].

Given the high mortality and rapid progression of TSS, prevention strategies at multiple levels are essential to reduce incidence and recurrence. No single intervention has proven universally effective, but a combination of targeted education, source control, and, for household contacts of invasive GAS, antibiotic prophylaxis can substantially lower risk ^[75]^B2b^[155]^D5.

Primary Prevention

Primary prevention focuses on interrupting the chain of colonization and toxin production. For menstrual TSS, the single most impactful measure is patient education: removing tampons or menstrual cups promptly, alternating with pads, and using the lowest absorbency product. Any patient with a history of TSS should avoid tampons entirely. For surgical or wound-associated TSS, meticulous wound care, timely removal of nasal packing, and avoiding unnecessary packing altogether are critical. A systematic review found no evidence that prophylactic systemic with nasal packing prevent TSS, and the studies were underpowered to detect a difference ^[153]^D5. Similarly, antibiotic prophylaxis in burn patients does not prevent TSS in low-grade burns, but may be considered in severe burns requiring mechanical ventilation (Grade 2B) ^[154]^B2a^[157]^A1a. The vast majority of burn patients do not benefit from systemic prophylaxis; adequate nursing care suffices ^[159]^C4.

Secondary Prevention: Preventing Recurrence

After an episode of staphylococcal TSS, recurrence is well documented, particularly in menstrual cases. The cornerstone is complete avoidance of tampons, menstrual cups, and vaginal barrier contraceptives. For streptococcal TSS, close contacts of index cases have a dramatically increased risk: the incidence rate among household contacts is 2011 times higher than the population incidence within the first month ^[75]^B2b. This observation supports offering antibiotic prophylaxis to household contacts, although the optimal regimen is not established. Clindamycin (10 mg/kg/dose, max 900 mg, every 8 hours) or a beta-lactam is often used, with a duration of 7 days ^[75]^B2b^[155]^D5.

Vaccine Development

No licensed vaccine currently exists for TSS. However, a recombinant detoxified toxic shock syndrome toxin-1 variant (rTSST-1v) vaccine has completed a phase 1 trial (NCT02340338) demonstrating safety, tolerability, and immunogenicity in healthy adults ^[53]^A1b. A subsequent study confirmed that vaccination induces high-titer neutralizing antibodies that persist for months: after a booster, 78.8% of subjects had T cell activation neutralization titers ≥1:1000 ^[158]^C4. This vaccine is not yet available for clinical use, but represents a promising avenue for primary prevention, especially for high-risk populations such as burn patients or those with recurrent TSS.

Patient Education

Key educational points for all patients: recognize early signs of TSS (sudden fever, diffuse rash, hypotension, conjunctival injection), remove any vaginal foreign body or wound packing immediately, and seek emergency care. For postpartum women, awareness of puerperal TSS is critical, as delayed diagnosis contributed to preventable maternal deaths in French surveillance data ^[132]^C4.

No routine screening for TSS is recommended. The focus remains on clinical vigilance and prompt action when risk factors are present.

Pearl: For any patient with a history of staphylococcal TSS, the single most effective preventive measure is lifelong avoidance of tampons and other vaginal inserts, this alone reduces recurrence from >30% to nearly zero. For household contacts of invasive GAS, offer clindamycin prophylaxis for 7 days, as the risk of TSS in contacts is >2000-fold higher than background ^[75]^B2b.

Special Hosts and Populations

▸Children with TSS often lack rash, leading to delayed treatment; mortality is lower (4.2%) than in adults but still significant.
▸Pregnancy, especially the postpartum period, carries a high risk of progression to streptococcal TSS; antenatal infections have a 21.7% mortality.
▸Elderly patients have the highest incidence and case-fatality rate (36%) for streptococcal TSS; increasing age is an independent risk factor for death.
▸Immunocompromised hosts (HIV, diabetes, malignancy) have worse outcomes, with immunosuppression conferring an OR of 4.02 for ICU mortality.

HY High Yield: In children with suspected TSS, the absence of rash should not delay initiation of clindamycin and source control; delayed treatment (mean 3.37 days without rash) is associated with prolonged hospitalization and complications [87].

Prevention strategies must be tailored to the populations at highest risk, where host factors fundamentally alter the presentation, microbiology, and outcomes of both staphylococcal and streptococcal TSS.

Children

Children represent a distinct population due to high rates of S. aureus colonization and unique clinical presentations. S. aureus nasopharyngeal carriage is present in 55% of healthy preschool children, with toxic shock syndrome toxin-1 (TSST-1) genes detected in 24% of isolates ^[35]^B2b. In pediatric TSS, clinical features often include pyuria (50% in streptococcal TSS), pulmonary involvement (85%), and coagulopathy (92% in nonstreptococcal TSS) ^[87]^C4. Rash may be absent, leading to delayed diagnosis and treatment (mean 3.37 days vs 0.87 days with rash) ^[87]^C4. Mortality in pediatric streptococcal TSS is lower than in adults: 4.2% in a multicenter study ^[111]^B2b and 2-10% in recent reviews ^[65]^D5. Intravenous immunoglobulin (IVIG) use in children is not associated with improved outcomes in observational studies ^[111]^B2b; a feasibility randomized trial showed no difference in secondary clinical outcomes ^[120]^A1b. Thermal injury-associated TSS in children carries a mortality of 8.3% ^[81]^C4. Multisystem inflammatory syndrome in children (MIS-C) shares features with TSS and is more closely related to TSS than to ^[147]^D5; it disproportionately affects Black and Hispanic children ^[165]^D5.

Pregnancy and the Puerperium

Pregnancy and the postpartum period are high-risk for invasive group A streptococcal (GAS) infection and TSS. The incidence of invasive GAS in pregnancy is 0.12 per 1000 livebirths in high-income countries ^[74]^B2a. Most infections occur postpartum (91.9%), with bacteremia in 49% and endometritis in 45.9% ^[162]^B2a. Puerperal sepsis progresses to streptococcal TSS in one-third of cases ^[162]^B2a. The overall case-fatality ratio is 2%, but antenatal cases have substantially higher mortality (21.7%) ^[162]^B2a. Septic abortion carries a 13.6% mortality ^[162]^B2a. Early recognition and aggressive are critical ^[162]^B2a.

Elderly

Incidence of invasive GAS is highest in persons aged ≥65 years: 9.4 per 100,000 population ^[148]^B2b. The case-fatality rate for streptococcal TSS in this age group is 36% ^[148]^B2b. Increasing age is an independent risk factor for death ^[148]^B2b. The incidence of invasive GAS has risen over time, with the highest rates consistently in older adults ^[23]^B2c.

Immunocompromised Hosts

Immunosuppression is an independent risk factor for ICU mortality in invasive GAS (odds ratio [OR] 4.02) ^[163]^B3b. Diabetes also increases mortality risk (OR 3.92) ^[163]^B3b. HIV infection can predispose to unusual presentations, such as staphylococcal enterocolitis leading to TSS ^[6]^C4. Patients with malignancy or other immunocompromising conditions are at risk for severe complications, as illustrated by a case of with streptococcal TSS ^[166]^C4.

Other High-Risk Groups

Injection drug use is a risk factor for 20% of severe GAS cases in the United Kingdom ^[46]^C4.
People experiencing homelessness, people who inject drugs, and residents of long-term care facilities have substantially elevated GAS incidence rates ^[23]^B2c.
Nonsteroidal anti-inflammatory drugs and alcoholism are independently associated with increased risk of streptococcal TSS ^[46]^C4.
Racial and ethnic disparities exist: incidence is higher among American Indian/Alaska Native and Black populations ^[23]^B2c, and among Māori and Pacific Islanders in New Zealand ^[47]^C4.
Low socioeconomic status is associated with higher incidence ^[47]^C4.

Pearl: In children, the absence of rash should not delay TSS treatment; in pregnancy, antenatal GAS infection carries a disproportionately high mortality (21.7%); in the elderly, age itself is an independent risk factor for death, with a 36% case-fatality rate for streptococcal TSS.

Key Considerations in Special Populations for TSS

Population	Key Features	Mortality / Risk	Special Considerations
Children	High S. aureus carriage (55%); TSST-1 in 24% ^[35]^B2b; pyuria, pulmonary involvement, coagulopathy common ^[87]^C4; rash often absent	4.2% (streptococcal) ^[111]^B2b; 8.3% (thermal injury) ^[81]^C4	Delayed treatment if no rash; IVIG not proven beneficial ^[111]^B2b^[120]^A1b
Pregnancy / Puerperium	91.9% postpartum; bacteremia 49%; endometritis 45.9% ^[162]^B2a	Overall CFR 2%; antenatal CFR 21.7% ^[162]^B2a	One-third of puerperal sepsis progresses to STSS; early aggressive management critical ^[162]^B2a
Elderly (≥65 yr)	Highest incidence: 9.4/100,000 ^[148]^B2b	STSS CFR 36% ^[148]^B2b	Age independent risk factor for death ^[148]^B2b
Immunocompromised	HIV, diabetes, malignancy, immunosuppression	ICU mortality OR 4.02 (immunosuppression), OR 3.92 (diabetes) ^[163]^B3b	Unusual presentations possible (e.g., staphylococcal enterocolitis) ^[6]^C4
Other high-risk	Injection drug use, homelessness, LTC residents, NSAID/alcohol use, racial/ethnic minorities	Elevated incidence rates ^[23]^B2c^[46]^C4^[47]^C4	Socioeconomic disparities; consider prophylaxis in close contacts ^[75]^B2b

References

[1]
Strandberg KL, Peterson ML, Schaefers MM et al.. “Reduction in Staphylococcus aureus growth and exotoxin production and in vaginal interleukin 8 levels due to glycerol monolaurate in tampons.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2009). PMID: 19863450 ↗
L1RCTCited in: Definition, Classification and Causative Organisms, Microbiology and Pathogenesis, History and Evolution of Treatment
[2]
Berger S, Kunerl A, Wasmuth S et al.. “Menstrual toxic shock syndrome: case report and systematic review of the literature.” The Lancet. Infectious diseases (2019). PMID: 31151811 ↗
L4SR_OBSCited in: Definition, Classification and Causative Organisms, Microbiology and Pathogenesis, Epidemiology, Transmission and Risk Factors, Clinical Presentation, Diagnosis and Workup, Complications
[3]
Anpalagan K, Dotel R, MacFadden DR et al.. “Does Adjunctive Clindamycin Have a Role in Staphylococcus aureus Bacteremia? A Protocol for the Adjunctive Treatment Domain of the Staphylococcus aureus Network Adaptive Platform (SNAP) Randomized Controlled Trial.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2024). PMID: 38801783 ↗
L5TRIAL_NONRANDOMCited in: Definition, Classification and Causative Organisms, Microbiology and Pathogenesis, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship
[4]
Johansson L, Thulin P, Low DE et al.. “Getting under the skin: the immunopathogenesis of Streptococcus pyogenes deep tissue infections.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2010). PMID: 20491545 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Microbiology and Pathogenesis, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
[5]
Dahmann S, Kueckelhaus M, Wiebringhaus P et al.. “Maternal mastitis and streptococcal toxic shock syndrome risk from breastfeeding children with scarlet fever: case report and literature review.” The Lancet. Infectious diseases (2025). PMID: 40252684 ↗
L4CASE_REPORTCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Empiric Management, Acute Care and Source Control, Complications
[6]
Kotler DP, Sandkovsky U, Schlievert PM et al.. “Toxic shock-like syndrome associated with staphylococcal enterocolitis in an HIV-infected man.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2007). PMID: 17516392 ↗
L4CASE_REPORTCited in: Definition, Classification and Causative Organisms, Complications, Special Hosts and Populations
[7]
Lacy MD, Horn K. “Nosocomial transmission of invasive group a streptococcus from patient to health care worker.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2009). PMID: 19580415 ↗
L4CASE_REPORTCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Diagnosis and Workup
[8]
Assimacopoulos AP, Strandberg KL, Rotschafer JH et al.. “Extreme pyrexia and rapid death due to Staphylococcus aureus infection: analysis of 2 cases.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2009). PMID: 19191649 ↗
L4CASE_REPORTCited in: Definition, Classification and Causative Organisms, Microbiology and Pathogenesis
[9]
Lappin E, Ferguson AJ. “Gram-positive toxic shock syndromes.” The Lancet. Infectious diseases (2009). PMID: 19393958 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Microbiology and Pathogenesis, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Complications
[10]
Aronoff DM, Marrazzo JM. “Infections caused by Clostridium perfringens and Paeniclostridium sordellii after unsafe abortion.” The Lancet. Infectious diseases (2022). PMID: 36155670 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Clinical Presentation, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Special Hosts and Populations
[11]
Schlievert PM, Davis CC. “Device-Associated Menstrual Toxic Shock Syndrome.” Clinical microbiology reviews (2020). PMID: 32461307 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Microbiology and Pathogenesis, Epidemiology, Transmission and Risk Factors, History and Evolution of Treatment
[12]
Walker MJ, Barnett TC, McArthur JD et al.. “Disease manifestations and pathogenic mechanisms of Group A Streptococcus.” Clinical microbiology reviews (2014). PMID: 24696436 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Microbiology and Pathogenesis, Epidemiology, Transmission and Risk Factors, Empiric Management, Acute Care and Source Control, Antimicrobial Resistance and Stewardship, Prognosis and Natural History, Prevention and Infection Control
[13]
Xie O, Davies MR, Tong SYC. “Streptococcus dysgalactiae subsp. equisimilis infection and its intersection with Streptococcus pyogenes.” Clinical microbiology reviews (2024). PMID: 38856686 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Empiric Management, Acute Care and Source Control, Antimicrobial Resistance and Stewardship
[14]
Nelson GE, Pondo T, Toews KA et al.. “Epidemiology of Invasive Group A Streptococcal Infections in the United States, 2005-2012.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2016). PMID: 27105747 ↗
L2OTHERCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors
[15]
Horn DL, Roberts EA, Shen J et al.. “Outcomes of β-Hemolytic Streptococcal Necrotizing Skin and Soft-tissue Infections and the Impact of Clindamycin Resistance.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2021). PMID: 33151283 ↗
L2OTHERCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship, Complications
[16]
Chi CY, Wang SM, Lin HC et al.. “A clinical and microbiological comparison of Staphylococcus aureus toxic shock and scalded skin syndromes in children.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2005). PMID: 16355327 ↗
L3OTHERCited in: Definition, Classification and Causative Organisms, Microbiology and Pathogenesis, Empiric Management, Acute Care and Source Control, Antimicrobial Resistance and Stewardship, Special Hosts and Populations
[17]
Linnér A, Darenberg J, Sjölin J et al.. “Clinical efficacy of polyspecific intravenous immunoglobulin therapy in patients with streptococcal toxic shock syndrome: a comparative observational study.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2014). PMID: 24928291 ↗
L2OTHERCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Clinical Presentation, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Prognosis and Natural History
[18]
Robert J, Tristan A, Cavalié L et al.. “Panton-valentine leukocidin-positive and toxic shock syndrome toxin 1-positive methicillin-resistant Staphylococcus aureus: a French multicenter prospective study in 2008.” Antimicrobial agents and chemotherapy (2011). PMID: 21220529 ↗
L4COHORTCited in: Definition, Classification and Causative Organisms, Microbiology and Pathogenesis, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
[19]
Inada M, Iwamoto N, Nomoto H et al.. “Characteristics of Streptococcal Toxic Shock Syndrome Caused by Different Beta-hemolytic Streptococci Species: A Single-center Retrospective Study.” Open forum infectious diseases (2024). PMID: 39296344 ↗
L2COHORTCited in: Definition, Classification and Causative Organisms
[20]
Dufort EM, Koumans EH, Chow EJ et al.. “Multisystem Inflammatory Syndrome in Children in New York State.” The New England journal of medicine (2020). PMID: 32598830 ↗
L4OTHERCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Clinical Presentation, Complications, Special Hosts and Populations
[21]
Baxter M, Morgan M. “Streptococcal Toxic Shock Syndrome Caused by Group G Streptococcus, United Kingdom.” Emerging infectious diseases (2017). PMID: 27983491 ↗
L4CASE_REPORTCited in: Definition, Classification and Causative Organisms, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
[22]
Sendi P, Johansson L, Dahesh S et al.. “Bacterial phenotype variants in group B streptococcal toxic shock syndrome.” Emerging infectious diseases (2009). PMID: 19193266 ↗
L4CASE_REPORTCited in: Definition, Classification and Causative Organisms, Antimicrobial Resistance and Stewardship
[23]
Gregory CJ, Okaro JO, Reingold A et al.. “Invasive Group A Streptococcal Infections in 10 US States.” JAMA (2025). PMID: 40193120 ↗
L2OTHERCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship, Special Hosts and Populations
[24]
Cheung EW, Zachariah P, Gorelik M et al.. “Multisystem Inflammatory Syndrome Related to COVID-19 in Previously Healthy Children and Adolescents in New York City.” JAMA (2020). PMID: 32511676 ↗
L4OTHERCited in: Definition, Classification and Causative Organisms, Clinical Presentation, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Complications, Special Hosts and Populations
[25]
Schlievert PM, Merriman JA, Salgado-Pabón W et al.. “Menaquinone analogs inhibit growth of bacterial pathogens.” Antimicrobial agents and chemotherapy (2013). PMID: 23959313 ↗
L5OTHERCited in: Definition, Classification and Causative Organisms, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
[26]
Kim D, Hong JS, Yoon EJ et al.. “Toxic Shock Syndrome Toxin 1-Producing Methicillin-Resistant Staphylococcus aureus of Clonal Complex 5, the New York/Japan Epidemic Clone, Causing a High Early-Mortality Rate in Patients with Bloodstream Infections.” Antimicrobial agents and chemotherapy (2019). PMID: 31501145 ↗
L2OTHERCited in: Definition, Classification and Causative Organisms, Microbiology and Pathogenesis, Epidemiology, Transmission and Risk Factors, Diagnosis and Workup, Antimicrobial Resistance and Stewardship, Prognosis and Natural History
[27]
Jekle A, Yoon J, Zuck M et al.. “NVC-422 inactivates Staphylococcus aureus toxins.” Antimicrobial agents and chemotherapy (2012). PMID: 23208720 ↗
L5OTHERCited in: Definition, Classification and Causative Organisms, Microbiology and Pathogenesis, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
[28]
Schlievert PM. “Chitosan malate inhibits growth and exotoxin production of toxic shock syndrome-inducing Staphylococcus aureus strains and group A streptococci.” Antimicrobial agents and chemotherapy (2007). PMID: 17576832 ↗
L5OTHERCited in: Definition, Classification and Causative Organisms, Microbiology and Pathogenesis, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
[29]
McNamara PJ, Syverson RE, Milligan-Myhre K et al.. “Surfactants, aromatic and isoprenoid compounds, and fatty acid biosynthesis inhibitors suppress Staphylococcus aureus production of toxic shock syndrome toxin 1.” Antimicrobial agents and chemotherapy (2009). PMID: 19223628 ↗
L5OTHERCited in: Definition, Classification and Causative Organisms, Microbiology and Pathogenesis
[30]
Wang K, Gan L, Jiang L et al.. “Neutralization of staphylococcal enterotoxin B by an aptamer antagonist.” Antimicrobial agents and chemotherapy (2015). PMID: 25624325 ↗
L5OTHERCited in: Definition, Classification and Causative Organisms, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment
[31]
Denis O, Deplano A, Nonhoff C et al.. “In vitro activities of ceftobiprole, tigecycline, daptomycin, and 19 other antimicrobials against methicillin-resistant Staphylococcus aureus strains from a national survey of Belgian hospitals.” Antimicrobial agents and chemotherapy (2006). PMID: 16870758 ↗
L5OTHERCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship
[32]
Li MH, Luo YH, Lin CF et al.. “Dextromethorphan efficiently increases bactericidal activity, attenuates inflammatory responses, and prevents group a streptococcal sepsis.” Antimicrobial agents and chemotherapy (2011). PMID: 21199930 ↗
L5OTHERCited in: Definition, Classification and Causative Organisms, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Prognosis and Natural History
[33]
Lu SL, Tsai CY, Luo YH et al.. “Kallistatin modulates immune cells and confers anti-inflammatory response to protect mice from group A streptococcal infection.” Antimicrobial agents and chemotherapy (2013). PMID: 23959316 ↗
L5OTHERCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Empiric Management, Acute Care and Source Control, Prognosis and Natural History
[34]
Budimir A, Deurenberg RH, Plecko V et al.. “Molecular characterization of methicillin-resistant Staphylococcus aureus bloodstream isolates from Croatia.” The Journal of antimicrobial chemotherapy (2005). PMID: 16339843 ↗
L4OTHERCited in: Definition, Classification and Causative Organisms, Microbiology and Pathogenesis, Epidemiology, Transmission and Risk Factors, Diagnosis and Workup, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship
[35]
Blumental S, Deplano A, Jourdain S et al.. “Dynamic pattern and genotypic diversity of Staphylococcus aureus nasopharyngeal carriage in healthy pre-school children.” The Journal of antimicrobial chemotherapy (2013). PMID: 23515249 ↗
L2OTHERCited in: Definition, Classification and Causative Organisms, Microbiology and Pathogenesis, Epidemiology, Transmission and Risk Factors, Diagnosis and Workup, Antimicrobial Resistance and Stewardship, Special Hosts and Populations
[36]
Mlynarczyk-Bonikowska B, Rudnicka L. “The Pathogenicity Mechanisms of Staphylococcus aureus.” International journal of molecular sciences (2025). PMID: 41465232 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Microbiology and Pathogenesis, History and Evolution of Treatment
[37]
Bartalucci C, Sepulcri C, Portunato F et al.. “Advances and updates in antibiotic combination therapy.” Expert review of anti-infective therapy (2025). PMID: 41292268 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Severity Assessment and Risk Stratification, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship
[38]
Weaver C. “Necrotizing Soft Tissue Infections.” The Medical clinics of North America (2025). PMID: 40185551 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Clinical Presentation
[39]
Focardi M, Faccioli S, Defraia B et al.. “Fatal Paraclostridium sordellii Infection: Post-Mortem Assessment and Review of the Literature.” Pathogens (Basel, Switzerland) (2025). PMID: 40732749 ↗
L4CASE_REPORTCited in: Definition, Classification and Causative Organisms, Clinical Presentation, History and Evolution of Treatment
[40]
Ujiie M. “Emerging Trends in Streptococcal Toxic Shock Syndrome, Japan.” Emerging infectious diseases (2024). PMID: 39992805 ↗
L4OTHERCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors
[41]
Sharma H, Smith D, Turner CE et al.. “Clinical and Molecular Epidemiology of Staphylococcal Toxic Shock Syndrome in the United Kingdom.” Emerging infectious diseases (2018). PMID: 29350159 ↗
L4OTHERCited in: Definition, Classification and Causative Organisms, Microbiology and Pathogenesis, Epidemiology, Transmission and Risk Factors, Antimicrobial Resistance and Stewardship
[42]
Sendi P, El Hay MA, Brandt CM et al.. “Group B Streptococcal Toxic Shock Syndrome and covR/S Mutations Revisited.” Emerging infectious diseases (2017). PMID: 27983484 ↗
L4OTHERCited in: Definition, Classification and Causative Organisms, Microbiology and Pathogenesis, Epidemiology, Transmission and Risk Factors, Diagnosis and Workup, Prognosis and Natural History
[43]
Luk EY, Lo JY, Li AZ et al.. “Scarlet fever epidemic, Hong Kong, 2011.” Emerging infectious diseases (2012). PMID: 23018120 ↗
L4OTHERCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship, Complications, Special Hosts and Populations
[44]
Smit MA, Nyquist AC, Todd JK. “Infectious shock and toxic shock syndrome diagnoses in hospitals, Colorado, USA.” Emerging infectious diseases (2013). PMID: 24188357 ↗
L2OTHERCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Clinical Presentation, Diagnosis and Workup, Special Hosts and Populations
[45]
Yu H, Jing H, Chen Z et al.. “Human Streptococcus suis outbreak, Sichuan, China.” Emerging infectious diseases (2006). PMID: 16707046 ↗
L4OTHERCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Diagnosis and Workup
[46]
Lamagni TL, Neal S, Keshishian C et al.. “Severe Streptococcus pyogenes infections, United Kingdom, 2003-2004.” Emerging infectious diseases (2008). PMID: 18258111 ↗
L4OTHERCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Severity Assessment and Risk Stratification, Prognosis and Natural History, Special Hosts and Populations
[47]
Safar A, Lennon D, Stewart J et al.. “Invasive group A streptococcal infection and vaccine implications, Auckland, New Zealand.” Emerging infectious diseases (2011). PMID: 21749758 ↗
L4OTHERCited in: Definition, Classification and Causative Organisms, Prognosis and Natural History, Special Hosts and Populations
[48]
Zhao C, Ren R, Wu W et al.. “Fatal Panton-Valentine leukocidin-positive MSSA toxic shock syndrome: a call for rapid virulence detection and optimized antimicrobial therapy.” Frontiers in cellular and infection microbiology (2026). PMID: 42205483 ↗
L4CASE_REPORTCited in: Definition, Classification and Causative Organisms, Microbiology and Pathogenesis, Clinical Presentation, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
[49]
Alkhatatbeh A, Chen J, Chen Y et al.. “Group A β-hemolytic streptococcus causing purpura fulminans: two case reports.” Frontiers in immunology (2026). PMID: 41743702 ↗
L4CASE_REPORTCited in: Definition, Classification and Causative Organisms, Clinical Presentation, Diagnosis and Workup, Empiric Management, Acute Care and Source Control
[50]
Deng B, Wen W, Wang Z et al.. “Type 2 diabetes mellitus wake-up call: fatal streptococcal toxic shock syndrome triggered by the M1(UK) Streptococcus pyogenes - a case report with genomic insights.” BMC infectious diseases (2026). PMID: 41714973 ↗
L4CASE_REPORTCited in: Definition, Classification and Causative Organisms, Clinical Presentation, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
[51]
Huang L, Liu Z, Bai Z et al.. “A fatal pediatric case of meningitis and streptococcal toxic shock syndrome caused by emm12 Streptococcus pyogenes strain in Jiangsu, China, 2024.” Infection (2025). PMID: 40911167 ↗
L4CASE_REPORTCited in: Definition, Classification and Causative Organisms, Clinical Presentation, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship
[52]
Okaba K, Motomura A, Saito N et al.. “A case of suspected transmission of group A Streptococcus from a dead body with streptococcal toxic shock syndrome to an autopsy worker.” International journal of legal medicine (2025). PMID: 40590929 ↗
L4CASE_REPORTCited in: Definition, Classification and Causative Organisms, Diagnosis and Workup
[53]
Schwameis M, Roppenser B, Firbas C et al.. “Safety, tolerability, and immunogenicity of a recombinant toxic shock syndrome toxin (rTSST)-1 variant vaccine: a randomised, double-blind, adjuvant-controlled, dose escalation first-in-man trial.” The Lancet. Infectious diseases (2016). PMID: 27296693 ↗
L1RCTCited in: Microbiology and Pathogenesis, Empiric Management, Acute Care and Source Control, History and Evolution of Treatment, Complications, Prevention and Infection Control
[54]
Contou D, Colin G, Travert B et al.. “Menstrual Toxic Shock Syndrome: A French Nationwide Multicenter Retrospective Study.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2022). PMID: 33906228 ↗
L2COHORTCited in: Microbiology and Pathogenesis, Epidemiology, Transmission and Risk Factors, Clinical Presentation, Diagnosis and Workup, Severity Assessment and Risk Stratification, Empiric Management, Acute Care and Source Control, Prognosis and Natural History, Special Hosts and Populations
[55]
Verkaik NJ, Dauwalder O, Antri K et al.. “Immunogenicity of toxins during Staphylococcus aureus infection.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2010). PMID: 19947854 ↗
L3OTHERCited in: Microbiology and Pathogenesis, Special Hosts and Populations
[56]
Schlievert PM, Case LC, Strandberg KL et al.. “Superantigen profile of Staphylococcus aureus isolates from patients with steroid-resistant atopic dermatitis.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2008). PMID: 18419342 ↗
L3OTHERCited in: Microbiology and Pathogenesis, Diagnosis and Workup, Complications
[57]
Gillet Y, Vanhems P, Lina G et al.. “Factors predicting mortality in necrotizing community-acquired pneumonia caused by Staphylococcus aureus containing Panton-Valentine leukocidin.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2007). PMID: 17599308 ↗
L2OTHERCited in: Microbiology and Pathogenesis, Prognosis and Natural History
[58]
Yates TA, Parks T, Dodd PJ. “Quantifying Potential Immortal Time Bias in Observational Studies in Acute Severe Infection.” Open forum infectious diseases (2025). PMID: 40256040 ↗
L5TRIAL_NONRANDOMCited in: Microbiology and Pathogenesis, Empiric Management, Acute Care and Source Control, Prognosis and Natural History
[59]
Khounsarian F, Ranjbar D, Ahmad MI et al.. “Menstrual toxic shock syndrome: A systematic review of imaging findings.” Clinical imaging (2026). PMID: 41592513 ↗
L4SR_OBSCited in: Microbiology and Pathogenesis, Clinical Presentation, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Prognosis and Natural History
[60]
McGowan D, Kermani A, Sheagren J. “Investigating and Summarizing Information Resources Related to the Clinical Presentation and Diagnosis of Cutaneous Manifestations of Infectious Diseases in Patients With Skin of Color.” Open forum infectious diseases (2023). PMID: 38390461 ↗
L5REVIEW_NARRATIVECited in: Microbiology and Pathogenesis, Clinical Presentation
[61]
Smith K, Gould KA, Ramage G et al.. “Influence of tigecycline on expression of virulence factors in biofilm-associated cells of methicillin-resistant Staphylococcus aureus.” Antimicrobial agents and chemotherapy (2009). PMID: 19858261 ↗
L5OTHERCited in: Microbiology and Pathogenesis, Diagnosis and Workup, Empiric Management, Acute Care and Source Control
[62]
Kaneko H, Yanagi Y, Otake S et al.. “The emerging threat of methicillin-resistant Staphylococcus aureus (MRSA) clone ST22-PT, carrying both Panton-Valentine leucocidin and toxic shock syndrome toxin 1 genes.” The Journal of antimicrobial chemotherapy (2023). PMID: 36814074 ↗
L4OTHERCited in: Microbiology and Pathogenesis, Epidemiology, Transmission and Risk Factors
[63]
Pichereau S, Moran JJ, Hayney MS et al.. “Concentration-dependent effects of antimicrobials on Staphylococcus aureus toxin-mediated cytokine production from peripheral blood mononuclear cells.” The Journal of antimicrobial chemotherapy (2011). PMID: 21980070 ↗
L5OTHERCited in: Microbiology and Pathogenesis, Prognosis and Natural History
[64]
Deplano A, Hallin M, Bustos Sierra N et al.. “Persistence of the Staphylococcus aureus epidemic European fusidic acid-resistant impetigo clone (EEFIC) in Belgium.” The Journal of antimicrobial chemotherapy (2023). PMID: 37358399 ↗
L4OTHERCited in: Microbiology and Pathogenesis, Epidemiology, Transmission and Risk Factors, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship
[65]
van Kempen EB, Malmgren A, Elfving K et al.. “Clindamycin and intravenous immunoglobulins in pediatric invasive group A streptococcal disease: what is the evidence?” European journal of pediatrics (2026). PMID: 41714399 ↗
L5REVIEW_NARRATIVECited in: Microbiology and Pathogenesis, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Special Hosts and Populations
[66]
Destoop J, Senoune S, De-Waard A et al.. “Skin biopsy PCR enables rapid diagnosis of tattoo-associated staphylococcal toxic shock syndrome.” International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases (2026). PMID: 42155665 ↗
L4CASE_REPORTCited in: Microbiology and Pathogenesis, Clinical Presentation
[67]
Palaniappan V, Gopinath H, Baskar Murthy A et al.. “A narrative review of Catamenial dermatology: A glimpse into the menstrual symphony.” Indian journal of dermatology, venereology and leprology (2025). PMID: 40990961 ↗
L5REVIEW_NARRATIVECited in: Microbiology and Pathogenesis
[68]
Rallis D, Atzemoglou N, Kapetaniou K et al.. “Molecular Epidemiology Clinical Manifestations, Decolonization Strategies, and Treatment Options of Methicillin-Resistant Staphylococcus aureus Infection in Neonates.” Pathogens (Basel, Switzerland) (2025). PMID: 40005530 ↗
L5REVIEW_NARRATIVECited in: Microbiology and Pathogenesis, Antimicrobial Resistance and Stewardship
[69]
Dourdouna MM, Tatsi EB, Syriopoulou V et al.. “Proteomic Signatures of Multisystem Inflammatory Syndrome in Children (MIS-C) Associated with COVID-19: A Narrative Review.” Children (Basel, Switzerland) (2024). PMID: 39457139 ↗
L5REVIEW_NARRATIVECited in: Microbiology and Pathogenesis
[70]
Wang Q, Liu C, Liang T et al.. “Molecular epidemiology of clinical Staphylococcus aureus infections: circulating CC398 lineage with human-adapted genomic signatures and virulent ST5-SCCmec II MRSA.” Frontiers in microbiology (2026). PMID: 42459879 ↗
L4OTHERCited in: Microbiology and Pathogenesis
[71]
Luo X, Yuan Y, Chen K et al.. “Transcriptomic profiling of TSST-1-induced cytotoxicity and inflammatory responses in human vaginal epithelial cells.” BMC microbiology (2026). PMID: 42260350 ↗
L5OTHERCited in: Microbiology and Pathogenesis, Empiric Management, Acute Care and Source Control
[72]
Alzahrani N, Alzayer M, Alasmari F et al.. “Epidemiology, clinical and molecular characteristics of Staphylococcus argenteus isolates from a tertiary care hospital in Riyadh, Saudi Arabia.” International journal of medical microbiology : IJMM (2026). PMID: 42086004 ↗
L4OTHERCited in: Microbiology and Pathogenesis, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
[73]
Parks T, Wilson C, Curtis N et al.. “Polyspecific Intravenous Immunoglobulin in Clindamycin-treated Patients With Streptococcal Toxic Shock Syndrome: A Systematic Review and Meta-analysis.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2018). PMID: 29788397 ↗
L1SR_OBSCited in: Epidemiology, Transmission and Risk Factors, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Prognosis and Natural History
[74]
Sherwood E, Vergnano S, Kakuchi I et al.. “Invasive group A streptococcal disease in pregnant women and young children: a systematic review and meta-analysis.” The Lancet. Infectious diseases (2022). PMID: 35390294 ↗
L2SR_OBSCited in: Epidemiology, Transmission and Risk Factors, Prognosis and Natural History, Special Hosts and Populations
[75]
Carapetis JR, Jacoby P, Carville K et al.. “Effectiveness of clindamycin and intravenous immunoglobulin, and risk of disease in contacts, in invasive group a streptococcal infections.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2014). PMID: 24785239 ↗
L2OTHERCited in: Epidemiology, Transmission and Risk Factors, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Prevention and Infection Control, Special Hosts and Populations
[76]
Fay K, Onukwube J, Chochua S et al.. “Patterns of Antibiotic Nonsusceptibility Among Invasive Group A Streptococcus Infections-United States, 2006-2017.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2021). PMID: 34170310 ↗
L2OTHERCited in: Epidemiology, Transmission and Risk Factors, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship
[77]
Darenberg J, Luca-Harari B, Jasir A et al.. “Molecular and clinical characteristics of invasive group A streptococcal infection in Sweden.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2007). PMID: 17638193 ↗
L3OTHERCited in: Epidemiology, Transmission and Risk Factors, Clinical Presentation, Diagnosis and Workup, Special Hosts and Populations
[78]
Valenciano SJ, Onukwube J, Spiller MW et al.. “Invasive Group A Streptococcal Infections Among People Who Inject Drugs and People Experiencing Homelessness in the United States, 2010-2017.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2021). PMID: 32803254 ↗
L2OTHERCited in: Epidemiology, Transmission and Risk Factors
[79]
Ratnayake H, Eisen D, Adegboye O et al.. “Burden of invasive group a streptococcus infection in Australia: a systematic review and meta-analysis.” European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology (2026). PMID: 41961183 ↗
L1SR_OBSCited in: Epidemiology, Transmission and Risk Factors
[80]
O'Shaughnessy J, Chiu J, Shim T et al.. “Incidence and Risk Factors for Toxic Shock Syndrome After Endoscopic Sinus Surgery: A Systematic Review.” Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery (2024). PMID: 39413334 ↗
L4SR_OBSCited in: Epidemiology, Transmission and Risk Factors
[81]
Alrasheed MF, Alkhalaf H, Alqahtani AM et al.. “The Epidemiology of Pediatric Thermal Injury-associated Toxic Shock Syndrome: A Systematic Review.” Journal of burn care & research : official publication of the American Burn Association (2024). PMID: 39039892 ↗
L4SR_OBSCited in: Epidemiology, Transmission and Risk Factors, Complications, Prognosis and Natural History, Special Hosts and Populations
[82]
Hutcherson TC, Cieri-Hutcherson NE, Grosshans MA et al.. “Systematic Review of Intrauterine Contraceptive Use and the Development of Toxic Shock Syndrome.” Journal of pharmacy practice (2025). PMID: 39778119 ↗
L4SR_OBSCited in: Epidemiology, Transmission and Risk Factors, Clinical Presentation, Diagnosis and Workup
[83]
Abo YN, Oliver J, McMinn A et al.. “Increased burden of invasive group A streptococcal disease among Australian children, 2023-2024: a prospective cohort study.” The Lancet regional health. Western Pacific (2026). PMID: 42004581 ↗
L2COHORTCited in: Epidemiology, Transmission and Risk Factors
[84]
Auger N, Carrier FM, Waechter J et al.. “Long-term outcomes of patients with toxic shock syndrome: A matched cohort study.” The Journal of infection (2024). PMID: 38944286 ↗
L2COHORTCited in: Epidemiology, Transmission and Risk Factors, Complications
[85]
Davis K, Abo YN, Steer AC et al.. “Chains of misery: surging invasive group A streptococcal disease.” Current opinion in infectious diseases (2024). PMID: 39259691 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Transmission and Risk Factors, Antimicrobial Resistance and Stewardship
[86]
Miller KM, Lamagni T, Cherian T et al.. “Standardization of Epidemiological Surveillance of Invasive Group A Streptococcal Infections.” Open forum infectious diseases (2022). PMID: 36128405 ↗
L5OTHERCited in: Epidemiology, Transmission and Risk Factors, Complications, Special Hosts and Populations
[87]
Cook A, Janse S, Watson JR et al.. “Manifestations of Toxic Shock Syndrome in Children, Columbus, Ohio, USA, 2010-20171.” Emerging infectious diseases (2020). PMID: 32442091 ↗
L4OTHERCited in: Epidemiology, Transmission and Risk Factors, Clinical Presentation, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Special Hosts and Populations
[88]
Dunne EM, Hutton S, Peterson E et al.. “Increasing Incidence of Invasive Group A Streptococcus Disease, Idaho, USA, 2008-2019.” Emerging infectious diseases (2022). PMID: 35997313 ↗
L2OTHERCited in: Epidemiology, Transmission and Risk Factors
[89]
Lesher L, Devries A, Danila R et al.. “Evaluation of surveillance methods for staphylococcal toxic shock syndrome.” Emerging infectious diseases (2009). PMID: 19402965 ↗
L4OTHERCited in: Epidemiology, Transmission and Risk Factors, Clinical Presentation, Diagnosis and Workup
[90]
John CC, Niermann M, Sharon B et al.. “Staphylococcal toxic shock syndrome erythroderma is associated with superantigenicity and hypersensitivity.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2009). PMID: 19911998 ↗
L4CASE_REPORTCited in: Clinical Presentation, Diagnosis and Workup
[91]
Page AV, Kotb M, McGeer A et al.. “Systemic dysregulation of angiopoietin-1/2 in streptococcal toxic shock syndrome.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2011). PMID: 21460306 ↗
L3OTHERCited in: Clinical Presentation, Diagnosis and Workup
[92]
Kadri SS, Swihart BJ, Bonne SL et al.. “Impact of Intravenous Immunoglobulin on Survival in Necrotizing Fasciitis With Vasopressor-Dependent Shock: A Propensity Score-Matched Analysis From 130 US Hospitals.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2017). PMID: 28034881 ↗
L2OTHERCited in: Clinical Presentation, Diagnosis and Workup, Severity Assessment and Risk Stratification, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Complications, Prognosis and Natural History
[93]
Whittaker E, Bamford A, Kenny J et al.. “Clinical Characteristics of 58 Children With a Pediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS-CoV-2.” JAMA (2020). PMID: 32511692 ↗
L4OTHERCited in: Clinical Presentation, Diagnosis and Workup, Complications, Special Hosts and Populations
[94]
Mazur-Ejankowska NK, Ejankowski M, Grzybowska ME et al.. “Toxic Epidermal Necrolysis and Steven-Johnson Syndrome During the Postpartum Period: A Literature Review with a Rare Case Presentation.” Journal of clinical medicine (2025). PMID: 41517265 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation, Empiric Management, Acute Care and Source Control, Complications
[95]
Minami M, Kamimura T, Isaka M et al.. “Clindamycin-induced CovS-mediated regulation of the production of virulent exoproteins streptolysin O, NAD glycohydrolase, and streptokinase in Streptococcus pyogenes.” Antimicrobial agents and chemotherapy (2009). PMID: 19805566 ↗
L5OTHERCited in: Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship
[96]
Zhong D, He J, Jin J et al.. “Case Report: Fatal Streptococcus pyogenes infection secondary to closed femoral fracture.” Frontiers in medicine (2026). PMID: 41859151 ↗
L4CASE_REPORTCited in: Diagnosis and Workup, History and Evolution of Treatment
[97]
Kim YK, Yun KW, Choi EH et al.. “Epidemiology and clinical characteristics of invasive group A streptococcal infection in the Republic of Korea, 2015-2024: a nationwide multicenter study.” The Lancet regional health. Western Pacific (2026). PMID: 42281793 ↗
L4OTHERCited in: Diagnosis and Workup
[98]
de Gier B, Vlaminckx BJM, van Roon A et al.. “Risk of Household Secondary Invasive Group A Streptococcal Infections After a Prophylaxis Policy Change.” JAMA network open (2026). PMID: 41505128 ↗
L2OTHERCited in: Diagnosis and Workup
[99]
Chiappini E, Renni M, De Luca M et al.. “Invasive Group A Streptococcus infections in children during the post-pandemic period: results from a multicenter study in Italy.” Italian journal of pediatrics (2025). PMID: 41316382 ↗
L4OTHERCited in: Diagnosis and Workup
[100]
van Kempen EB, Tulling AJ, von Asmuth EGJ et al.. “Risk Factors for Severe Pediatric Invasive Group A Streptococcal Disease.” JAMA network open (2025). PMID: 40828532 ↗
L2OTHERCited in: Diagnosis and Workup
[101]
Hanada S, Wajima T, Takata M et al.. “Additional biomarkers and emm types associated with group A streptococcal toxic shock syndrome: a Japanese nationwide observational study.” European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology (2025). PMID: 40193020 ↗
L2OTHERCited in: Diagnosis and Workup
[102]
Ong PY, Patel M, Ferdman RM et al.. “Association of staphylococcal superantigen-specific immunoglobulin e with mild and moderate atopic dermatitis.” The Journal of pediatrics (2008). PMID: 18621391 ↗
L4TRIAL_NONRANDOMCited in: Severity Assessment and Risk Stratification
[103]
Amrith S, Hosdurga Pai V, Ling WW. “Periorbital necrotizing fasciitis -- a review.” Acta ophthalmologica (2012). PMID: 22520175 ↗
L4SR_OBSCited in: Severity Assessment and Risk Stratification
[104]
Suzuki T, Matsuo T, Kijima Y et al.. “Acute heart failure associated with toxic shock syndrome due to methicillin-susceptible Staphylococcus aureus during the postpartum period: case report and systematic literature review.” BMC cardiovascular disorders (2022). PMID: 36309644 ↗
L4SR_OBSCited in: Severity Assessment and Risk Stratification, Prognosis and Natural History
[105]
Khajuria A, Nadama HH, Gallagher M et al.. “Pediatric Toxic Shock Syndrome After a 7% Burn: A Case Study and Systematic Literature Review.” Annals of plastic surgery (2020). PMID: 31192868 ↗
L4SR_OBSCited in: Severity Assessment and Risk Stratification
[106]
So N, Leavitt E, Aleshin M et al.. “The use of etanercept for treatment of toxic epidermal necrolysis when toxic shock syndrome is in the differential.” Dermatologic therapy (2018). PMID: 30175438 ↗
L4CASE_REPORTCited in: Severity Assessment and Risk Stratification
[107]
Vinson AE, Dufort EM, Willis MD et al.. “Drug rash, eosinophilia, and systemic symptoms syndrome: Two pediatric cases demonstrating the range of severity in presentation--A case of vancomycin-induced drug hypersensitivity mimicking toxic shock syndrome and a milder case induced by minocycline.” Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies (2010). PMID: 20407399 ↗
L4CASE_REPORTCited in: Severity Assessment and Risk Stratification
[108]
Klug CD, Keay CR, Ginde AA. “Fatal toxic shock syndrome from an intrauterine device.” Annals of emergency medicine (2009). PMID: 19577335 ↗
L4CASE_REPORTCited in: Severity Assessment and Risk Stratification
[109]
Matsubara K, Mikamo H, Numa M et al.. “Three fatal cases of invasive serotype VI group B streptococcal infection.” The Journal of infection (2006). PMID: 16403580 ↗
L4CASE_REPORTCited in: Severity Assessment and Risk Stratification
[110]
Cortés-Penfield N, Ryder JH. “Should Linezolid Replace Clindamycin as the Adjunctive Antimicrobial of Choice in Group A Streptococcal Necrotizing Soft Tissue Infection and Toxic Shock Syndrome? A Focused Debate.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023). PMID: 36056891 ↗
L5OTHERCited in: Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship
[111]
Shah SS, Hall M, Srivastava R et al.. “Intravenous immunoglobulin in children with streptococcal toxic shock syndrome.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2009). PMID: 19788359 ↗
L2OTHERCited in: Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Special Hosts and Populations
[112]
Schrage B, Duan G, Yang LP et al.. “Different preparations of intravenous immunoglobulin vary in their efficacy to neutralize streptococcal superantigens: implications for treatment of streptococcal toxic shock syndrome.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2006). PMID: 16912949 ↗
L5OTHERCited in: Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
[113]
Chen CL, Cheng MH, Kuo CF et al.. “Dextromethorphan Attenuates NADPH Oxidase-Regulated Glycogen Synthase Kinase 3β and NF-κB Activation and Reduces Nitric Oxide Production in Group A Streptococcal Infection.” Antimicrobial agents and chemotherapy (2018). PMID: 29581121 ↗
L5OTHERCited in: Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Prognosis and Natural History
[114]
Wullt O, Utbult C, Carlson E et al.. “Intravenous Immunoglobulin Treatment in Patients With Streptococcal Toxic Shock Syndrome in Southern Sweden: A Retrospective Population-Based Study.” Open forum infectious diseases (2026). PMID: 41852552 ↗
L2OTHERCited in: Empiric Management, Acute Care and Source Control, Prognosis and Natural History
[115]
Kaneko S, Hatano M, Shimbo A et al.. “Serum Cytokine Profiling Differentiates Underlying Diseases in Cytokine Storm Syndrome.” Arthritis & rheumatology (Hoboken, N.J.) (2025). PMID: 40776831 ↗
L3OTHERCited in: Empiric Management, Acute Care and Source Control
[116]
Tsuchihashi Y, Tamura K, Matsumoto K et al.. “Comparative analysis of streptococcal toxic shock syndrome caused by three β-hemolytic streptococcal species in Japan.” International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases (2025). PMID: 40541772 ↗
L2OTHERCited in: Empiric Management, Acute Care and Source Control
[117]
Montero-Yeboles R, Saez-García LM, Ulloa-Santamaria E et al.. “Compassionate use of the Seraph® 100 affinity blood filter in pediatric refractory streptococcal septic shock: a case report.” Frontiers in pediatrics (2026). PMID: 42078547 ↗
L4CASE_REPORTCited in: Empiric Management, Acute Care and Source Control
[118]
Furuya K, Okumura N, Kaku Y et al.. “Overwhelming post-splenectomy infection caused by Streptococcus agalactiae, sequence type 10 with capsular serotype Ib encapsulating ST10/1b occurring 30 years after splenectomy: a case report.” Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy (2026). PMID: 41775142 ↗
L4CASE_REPORTCited in: Empiric Management, Acute Care and Source Control
[119]
Ayabe N, Komiya T, Nakamura I et al.. “Toxic Shock Syndrome Caused by Methicillin-resistant Staphylococcus aureus After Immediate Breast Reconstruction With Tissue Expander.” Plastic and reconstructive surgery. Global open (2026). PMID: 41602843 ↗
L4CASE_REPORTCited in: Empiric Management, Acute Care and Source Control
[120]
Portefaix A, Dhelens C, Recher M et al.. “High-dose intravenous immunoglobulin versus albumin 4% in paediatric toxic shock syndrome: a randomised controlled feasibility study.” Archives of disease in childhood (2024). PMID: 38360044 ↗
L1RCTCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment, Complications, Prognosis and Natural History, Special Hosts and Populations
[121]
Martins FR, Azevedo AC, Ganhão S et al.. “Anakinra and hepatotoxicity in pediatric rheumatology: a case series.” Pediatric rheumatology online journal (2023). PMID: 37803456 ↗
L4CASE_REPORTCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment, Special Hosts and Populations
[122]
Rahimi-Jamnani F, Moradi HR, Fateh A et al.. “The Therapeutic Efficacy of MS473, a Fully Human Single-Chain Variable Fragment Targeting Staphylococcus aureus Toxic Shock Syndrome Toxin-1, in a D-Galactosamine-Sensitized Mouse Model of Lethal Shock.” BMC microbiology (2025). PMID: 40011833 ↗
L5OTHERCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
[123]
Kang HJ, You J-Y, Kim SH et al.. “Characteristics of methicillin-resistant Staphylococcus aureus isolates from bovine mastitis milk in South Korea: molecular characteristics, biofilm, virulence, and antimicrobial resistance.” Microbiology spectrum (2024). PMID: 39436122 ↗
L5OTHERCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
[124]
Omar A, El-Banna TE, Sonbol FI et al.. “Potential antivirulence and antibiofilm activities of sub-MIC of oxacillin against MDR S. aureus isolates: an in-vitro and in-vivo study.” BMC microbiology (2024). PMID: 39123138 ↗
L5OTHERCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
[125]
Jarneborn A, Hu Z, Deshmukh M et al.. “Tofacitinib Treatment Suppresses CD4+ T-Cell Activation and Th1 Response, Contributing to Protection against Staphylococcal Toxic Shock.” International journal of molecular sciences (2024). PMID: 39000566 ↗
L5OTHERCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
[126]
Rana EA, Nizami TA, Islam MS et al.. “Antimicrobial resistance and virulence profiling of Staphylococcus pseudintermedius isolated from cats, Bangladesh.” The veterinary quarterly (2024). PMID: 38487883 ↗
L4OTHERCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
[127]
Yue Y, Chen K, Sun C et al.. “Antimicrobial peptidase lysostaphin at subinhibitory concentrations modulates staphylococcal adherence, biofilm formation, and toxin production.” BMC microbiology (2023). PMID: 37884887 ↗
L5OTHERCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
[128]
Darenberg J, Ihendyane N, Sjölin J et al.. “Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: a European randomized, double-blind, placebo-controlled trial.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2003). PMID: 12884156 ↗
L1RCTCited in: History and Evolution of Treatment
[129]
Davies HD, Low DE, Schwartz B et al.. “Evaluation of short-course therapy with cefixime or rifampin for eradication of pharyngeally carried group A streptococci. The Ontario GAS Study Group.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (1995). PMID: 8589159 ↗
L1RCTCited in: History and Evolution of Treatment
[130]
Eriksson BK, Andersson J, Holm SE et al.. “Epidemiological and clinical aspects of invasive group A streptococcal infections and the streptococcal toxic shock syndrome.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (1998). PMID: 9868656 ↗
L4OTHERCited in: History and Evolution of Treatment
[131]
Bansal N, Azeka E, Neunert C et al.. “Multisystem Inflammatory Syndrome Associated with COVID-19 Anti-thrombosis Guideline of Care for Children by Action.” Pediatric cardiology (2021). PMID: 34076713 ↗
L1GUIDELINECited in: History and Evolution of Treatment
[132]
Rigouzzo A, Tessier V, Jonard M et al.. “[Maternal deaths due to infections in France 2013-2015].” Gynecologie, obstetrique, fertilite & senologie (2020). PMID: 33166703 ↗
L4GUIDELINECited in: History and Evolution of Treatment, Prevention and Infection Control
[133]
Sica VP, Friberg MA, Teufel AG et al.. “Safety assessment scheme for menstrual cups and application for the evaluation of a menstrual cup comprised of medical grade silicone.” EBioMedicine (2022). PMID: 36370636 ↗
L4RCTCited in: History and Evolution of Treatment
[134]
Bergdoll MS, Crass BA, Reiser RF et al.. “A new staphylococcal enterotoxin, enterotoxin F, associated with toxic-shock-syndrome Staphylococcus aureus isolates.” Lancet (London, England) (1981). PMID: 6112412 ↗
L3OTHERCited in: History and Evolution of Treatment
[135]
Rello J, Tejada S, Campogiani L et al.. “Systemic infections associated with tattoos or permanent makeup: A systematic review.” Medicina clinica (2021). PMID: 33902933 ↗
L4SR_OBSCited in: History and Evolution of Treatment
[136]
Fey PD, Saïd-Salim B, Rupp ME et al.. “Comparative molecular analysis of community- or hospital-acquired methicillin-resistant Staphylococcus aureus.” Antimicrobial agents and chemotherapy (2003). PMID: 12499191 ↗
L3OTHERCited in: History and Evolution of Treatment
[137]
Kong D, Pan H, Wu H et al.. “Engaging Broader Stakeholders to Accelerate Group A Streptococcus Vaccine Development.” Vaccines (2025). PMID: 40733711 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment, Complications
[138]
Amerson SJ, Hoffman M, Abouzahr F et al.. “Sequential Extracorporeal Therapy of Pathogen Removal Followed by Cell-Directed Extracorporeal Therapy in Streptococcal Toxic Shock Syndrome Refractory to Venoarterial Extracorporeal Membrane Oxygenation: A Case Report.” Critical care explorations (2024). PMID: 38415021 ↗
L4CASE_REPORTCited in: History and Evolution of Treatment
[139]
Armeftis C, Ioannou A, Lazarou T et al.. “Staphylococcus epidermidis induced toxic shock syndrome (TSS) secondary to influenza infection.” BMC infectious diseases (2023). PMID: 37674134 ↗
L4CASE_REPORTCited in: History and Evolution of Treatment
[140]
Wang J, Ma C, Li M et al.. “Streptococcus pyogenes: Pathogenesis and the Current Status of Vaccines.” Vaccines (2023). PMID: 37766186 ↗
L5REVIEW_NARRATIVECited in: Antimicrobial Resistance and Stewardship
[141]
Guo D, Zhuang S, Lu Q et al.. “Case report: Abscesses in children caused by invasive group A Streptococcus.” Frontiers in medicine (2024). PMID: 39185468 ↗
L4CASE_REPORTCited in: Antimicrobial Resistance and Stewardship
[142]
Bennett CA, Almahal MA, Popovic K et al.. “Streptococcal infections: Emerging trends, clinical spectrum and global prevention effort.” The American journal of the medical sciences (2025). PMID: 41173102 ↗
L5REVIEW_NARRATIVECited in: Antimicrobial Resistance and Stewardship
[143]
Esposito S, Masetti M, Calanca C et al.. “Recent Changes in the Epidemiology of Group A Streptococcus Infections: Observations and Implications.” Microorganisms (2025). PMID: 40871375 ↗
L5REVIEW_NARRATIVECited in: Antimicrobial Resistance and Stewardship
[144]
Zulaika G, Otieno FO, Mason L et al.. “Menstrual cups to reduce bacterial vaginosis and STIs through reduced harmful sexual and menstrual practices among economically vulnerable women: protocol of a single arm trial in western Kenya.” BMC public health (2024). PMID: 39516733 ↗
L5TRIAL_NONRANDOMCited in: Complications, Special Hosts and Populations
[145]
Stevens DL, Bryant AE. “Complexities of cardiomyopathy in septic shock.” Current opinion in infectious diseases (2025). PMID: 40127058 ↗
L5REVIEW_NARRATIVECited in: Complications, Prognosis and Natural History
[146]
Ohashi A, Murayama MA, Miyabe Y et al.. “Streptococcal infection and autoimmune diseases.” Frontiers in immunology (2024). PMID: 38464518 ↗
L5REVIEW_NARRATIVECited in: Complications
[147]
Noval Rivas M, Arditi M. “Kawasaki Disease and Multisystem Inflammatory Syndrome in Children: Common Inflammatory Pathways of Two Distinct Diseases.” Rheumatic diseases clinics of North America (2023). PMID: 37331738 ↗
L5REVIEW_NARRATIVECited in: Complications, Special Hosts and Populations
[148]
O'Loughlin RE, Roberson A, Cieslak PR et al.. “The epidemiology of invasive group A streptococcal infection and potential vaccine implications: United States, 2000-2004.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2007). PMID: 17806049 ↗
L2OTHERCited in: Prognosis and Natural History, Special Hosts and Populations
[149]
Bartoszko JJ, Elias Z, Rudziak P et al.. “Prognostic factors for streptococcal toxic shock syndrome: systematic review and meta-analysis.” BMJ open (2022). PMID: 36456018 ↗
L2SR_OBSCited in: Prognosis and Natural History
[150]
Meier-Stephenson V, Hawkes MT, Burton C et al.. “A phase 1 randomized controlled trial of a peptide-based group A streptococcal vaccine in healthy volunteers.” Trials (2024). PMID: 39563457 ↗
L1RCTCited in: Prognosis and Natural History
[151]
Atchade E, De Tymowski C, Grall N et al.. “Toxic Shock Syndrome: A Literature Review.” Antibiotics (Basel, Switzerland) (2024). PMID: 38247655 ↗
L5REVIEW_NARRATIVECited in: Prognosis and Natural History
[152]
Guerra S, LaRock C. “Group A Streptococcus interactions with the host across time and space.” Current opinion in microbiology (2024). PMID: 38219421 ↗
L5REVIEW_NARRATIVECited in: Prognosis and Natural History
[153]
Lange JL, Peeden EH, Stringer SP. “Are prophylactic systemic antibiotics necessary with nasal packing? A systematic review.” American journal of rhinology & allergy (2017). PMID: 28716175 ↗
L5SR_OBSCited in: Prevention and Infection Control
[154]
Ramos G, Cornistein W, Cerino GT et al.. “Systemic antimicrobial prophylaxis in burn patients: systematic review.” The Journal of hospital infection (2017). PMID: 28629932 ↗
L2SR_OBSCited in: Prevention and Infection Control
[155]
Wilkins AL, Steer AC, Smeesters PR et al.. “Toxic shock syndrome - the seven Rs of management and treatment.” The Journal of infection (2017). PMID: 28646955 ↗
L5REVIEW_NARRATIVECited in: Prevention and Infection Control
[156]
Hsu JL, Safdar N. “Polyclonal immunoglobulins and hyperimmune globulins in prevention and management of infectious diseases.” Infectious disease clinics of North America (2011). PMID: 22054755 ↗
L5REVIEW_NARRATIVECited in: Prevention and Infection Control
[157]
Houschyar KS, Tapking C, Duscher D et al.. “[Antibiotic treatment of infections in burn patients - a systematic review].” Handchirurgie, Mikrochirurgie, plastische Chirurgie : Organ der Deutschsprachigen Arbeitsgemeinschaft fur Handchirurgie : Organ der Deutschsprachigen Arbeitsgemeinschaft fur Mikrochirurgie der Peripheren Nerven und Gefasse : Organ der V... (2019). PMID: 30763978 ↗
L1SR_OBSCited in: Prevention and Infection Control
[158]
Roetzer A, Stich N, Model N et al.. “High Titer Persistent Neutralizing Antibodies Induced by TSST-1 Variant Vaccine Against Toxic Shock Cytokine Storm.” Toxins (2020). PMID: 33023185 ↗
L4RCTCited in: Prevention and Infection Control
[159]
Chahed J, Ksia A, Selmi W et al.. “Burns injury in children: is antibiotic prophylaxis recommended?” African journal of paediatric surgery : AJPS (2014). PMID: 25323182 ↗
L4RCTCited in: Prevention and Infection Control
[160]
Smeesters PR, Drèze PA, Perez-Morga D et al.. “Group A Streptococcus virulence and host factors in two toddlers with rheumatic fever following toxic shock syndrome.” International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases (2009). PMID: 19828348 ↗
L4CASE_REPORTCited in: Prevention and Infection Control
[161]
Italiano CM, Toi CS, Chan SP et al.. “Prolonged varicella viraemia and streptococcal toxic shock syndrome following varicella vaccination of a health care worker.” The Medical journal of Australia (2009). PMID: 19374621 ↗
L4CASE_REPORTCited in: Prevention and Infection Control
[162]
Harris K, Proctor LK, Shinar S et al.. “Outcomes and management of pregnancy and puerperal group A streptococcal infections: A systematic review.” Acta obstetricia et gynecologica Scandinavica (2023). PMID: 36636775 ↗
L2SR_OBSCited in: Special Hosts and Populations
[163]
Orieux A, Prevel R, Dumery M et al.. “Invasive group A streptococcal infections requiring admission to ICU: a nationwide, multicenter, retrospective study (ISTRE study).” Critical care (London, England) (2024). PMID: 38167516 ↗
L3COHORTCited in: Special Hosts and Populations
[164]
Jorde I, Schreiber J, Stegemann-Koniszewski S. “The Role of Staphylococcus aureus and Its Toxins in the Pathogenesis of Allergic Asthma.” International journal of molecular sciences (2022). PMID: 36614093 ↗
L5REVIEW_NARRATIVECited in: Special Hosts and Populations
[165]
Asghar Z, Sharaf K, Butt FA et al.. “A global review of racial, ethnic and socio-economic disparities in multisystem inflammatory syndrome in children related to COVID-19.” Frontiers in public health (2022). PMID: 36339223 ↗
L5REVIEW_NARRATIVECited in: Special Hosts and Populations
[166]
Oyama S, Adachi-Katayama M, Okamoto K et al.. “Preseptal cellulitis with Streptococcus pyogenes complicated by streptococcal toxic shock syndrome: A case report and review of literature.” Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy (2023). PMID: 37024048 ↗
L4CASE_REPORTCited in: Special Hosts and Populations

Staphylococcal Toxic Shock Syndrome

Quick Reference

Overview and Recommendations

Background

Evaluation

Management

Board Review — High Yield

Deep Dive — Evidence Details

Definition, Classification and Causative Organisms

Also Called / Synonyms

Classification

Causative Organisms

Clinical Significance

Microbiology and Pathogenesis

Virulence Factors and Genomic Context

Superantigen Mechanism

Regulation of Toxin Production

Host Susceptibility

Mechanism Flowchart

Epidemiology, Transmission and Risk Factors

Incidence and Demographics

Temporal Trends and Seasonal Variation

Risk Factors

Transmission

Clinical Presentation

Presenting Symptoms

Neurological Examination Findings

Phenotypic Variants

Red Flags

Atypical Presentations

Diagnosis and Workup

History and Physical

Gold-Standard Test

Laboratory Studies

Imaging

Diagnostic Algorithm

Differential Diagnosis

Severity Assessment and Risk Stratification

Clinical Severity Assessment

Risk Factors for Poor Outcome

Implications for Site of Care and Therapy Intensity

Empiric Management, Acute Care and Source Control

Step 1: Immediate Source Control

Step 2: Empiric Antimicrobial Therapy

Step 3: Adjunctive Therapies

Step 4: Supportive Care and Monitoring

Step 5: Transition to Definitive Therapy

Controversies and Guideline Disagreement

Definitive Therapy: Dosing, PK/PD, Duration and De-escalation

Step 1: Confirm organism and susceptibility

Step 2: Select the definitive regimen

Step 3: Dosing, PK/PD, and monitoring

Step 4: Duration and IV-to-oral switch

Step 5: De-escalation

Controversies and Guideline Disagreement

History and Evolution of Treatment

The 1980s: Discovery and the Tampon Connection

The 1990s: Clindamycin Enters, IVIG Tested

The 2000s: CA-MRSA and Nonmenstrual TSS

Prevention and the GML Story

2010s-2020s: Vaccine and Novel Therapeutics

What Was Abandoned and Why

Antimicrobial Resistance and Stewardship

Resistance in Group A Streptococcus (GAS)

Resistance in Staphylococcus aureus

Stewardship Principles

Complications

Respiratory Monitoring

Autonomic Complications

DVT/PE Prophylaxis

Pain Management

Rehabilitation

Hospital-Acquired Complications

Complication Table

Prognosis and Natural History

Untreated Course

Treated Outcomes

Predictors of Mortality

Special Populations

Prevention and Infection Control

Resistance in (GAS)